

CURRICULUM VITAE

TATYANA (TANYA) SIMUNI, MD

ARTHUR C. NIELSEN JR. PROFESSOR OF NEUROLOGY
Director, Parkinson's Disease and Movement Disorders Center

Office Address: Northwestern University, Feinberg School of Medicine
Department of Neurology
710 North Lake Shore Drive
Abbott Hall, 11th Floor
Chicago, IL 60611
312-503-2970
312-908-5073 (FAX)
tsimuni@nm.org

Citizenship: USA

EDUCATION

1979 - 82 B.S. Leningrad Medical School
1982 - 85 M.D. Leningrad Medical School*
*6 year Medical Program

POST GRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS

1985 - 87 Intern/Resident in Medicine, Leningrad Hospital #4
Leningrad, Russia
1990 - 91 Intern in Medicine, Albert Einstein Hospital, Philadelphia
1991 - 94 Resident in Neurology, Temple University Hospital,
Philadelphia
1994 - 95 Fellowship, Clinical Neurophysiology, Temple University Hospital, Philadelphia
1995 - 96 Fellowship, Movement Disorders, Parkinson's Disease and Movement Disorders Center,
Graduate Neurological Center, University of Pennsylvania, Philadelphia
2013 Kellogg School of Business Northwestern University Leadership Course (90 hour consolidated
curriculum)

POST GRADUATE RESEARCH TRAINING

1988 - 89 Research Associate, Laboratory of A. Salvaggio, MD
Department of Nephrology, Medical College of Pennsylvania
1989 - 90 Research Associate, Laboratory of L. Iacovitti, PhD
Department of Neurology, Hahnemann University Medical School

SPECIALTY CERTIFICATION

1996 American Board of Psychiatry and Neurology
1997 Added Qualification in Neurophysiology
2005 American Board of Psychiatry and Neurology Recertification
2015 American Board of Psychiatry and Neurology Recertification

LICENSURE

State of Illinois
Commonwealth of Pennsylvania (inactive status)

ACADEMIC HONORS AND AWARDS

1979	Award for outstanding academic performance (Golden Medal)
1985	Graduated among the top 10 students of Medical School Class of 1985
2003, 2006	The John Kessler Teaching Award. Department of Neurology. Northwestern University Medical School, Chicago, IL
2008	Northwestern Medical Foundation Physician Excellence Award in Clinical Leadership (one award for > 500 faculty)
2010 - 2014	Arthur C. Nielsen Research Professor of Parkinson's Disease and Movement Disorders Cures Within Reach Research Patient Impact Award, Bioscience Awards of the Midwest, Chicago, IL
2017	William Langston award, Michael J. Fox Foundation Annual award voted by the MJFF staff to recognize investigator who has contributed the most to MJFF mission

FACULTY APPOINTMENTS

1994 - 95	Instructor in Neurology , Temple University Hospital
1997- 00	Clinical Assistant Professor , Department of Neurology University of Pennsylvania
2000 - 2006	Assistant Professor , Department of Neurology Northwestern University Feinberg School of Medicine, Chicago, IL
2006 - 2012	Associate Professor , Department of Neurology Northwestern University Feinberg School of Medicine, Chicago, IL
2012-	Arthur C. Nielsen Research Professor , Department of Neurology Northwestern University Feinberg School of Medicine, Chicago, IL

HOSPITAL STAFF APPOINTMENTS

1996 - 97	Teaching Attending, Department of Neurology MacNeal Hospital/ Academic Affiliate of University of Chicago
1996 - 97	Co- Director Neurophysiology Laboratory MacNeal Hospital
1997 - 2000	Attending Neurologist Pennsylvania Hospital, Philadelphia
1999 - 00	Medical Director , Movement Disorders Surgical Program Parkinson's Disease and Movement Disorders Center, Pennsylvania Hospital, University of PA
2000 -	Attending Neurologist Northwestern Memorial Hospital, Chicago, IL

ADMINISTRATIVE APPOINTMENTS

1993 - 1994	Chief Resident, Neurology Temple University Hospital
2001 - 2014	Residency Program Director, Department of Neurology Northwestern University Feinberg School of Medicine, Chicago, IL
2000 -	Director , Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL
2001-	Director . Parkinson's Foundation Center of Excellence. Northwestern University Feinberg School of Medicine.
2017-	Director , Advanced neurology fellowship (R25 trainees)
2019-	Director , Movement Disorders fellowship (3 fellows/ year)

UNIVERSITY AND HOSPITAL COMMITTEE SERVICE

2002 - 2005	Member, NMH Pharmacy Committee Northwestern Memorial Hospital, Chicago, IL
2002 - 2005	Member, McGaw Graduate Medical Education Committee Northwestern Memorial Hospital, Chicago, IL
2001- 2008 - 2012-	Executive Committee, Dept of Neurology, Northwestern University Executive Committee Clinical Trials Unit, Department of Neurology, Northwestern University Executive Committee for the Enhancement of Clinical Trials, Clinical research Committee, Northwestern University Feinberg School of Medicine
2012-	Academic Promotion and Tenure Committee (APT), Northwestern University Feinberg School of Medicine
2014-	NUCATS Advisory Council
2014-	Northwestern Memorial Hospital Care Team Leadership Forum
2015-	Academic Promotion and Tenure Committee (APT), Northwestern University Feinberg School of Medicine, Department of Neurology
2014- 2016	FSM endowed professorship appointment review committee
2016-	FSM Executive Clinical Research Council (10 members appointed by the Dean of Research)

MEMBERSHIPS IN PROFESSIONAL AND ACADEMIC SOCIETIES

American Academy of Neurology (1994-)	
2002 -	Member- Movement Disorders Section
2003 - 2013	Member- Consortium of Residency Program Directors
2011, 2014	<u>Abstracts reviewer</u> for the annual meeting
2013	<u>Co-Chair</u> , Scientific Platform Session. Therapeutics Parkinson's Disease Mentor. Research Career development symposium Abstracts reviewer
2014	<u>Reviewer</u> . Movement Disorders Abstracts. 2014 AAN Annual Meeting. Philadelphia, PA. April 26–May 3, 2014.
2014	Ecuador Neurology Project, Invited Faculty
2015	<u>Co-Chair</u> , Scientific Platform Session. Genetics Parkinson's Disease Abstracts reviewer
2015	Reviewer. Movement Disorders Abstracts. 2015 AAN Annual Meeting. Washington, DC. April 18–25, 2015.
2016	<u>Co-Chair</u> , Review Movement Disorders Abstracts. 2016 AAN Annual Meeting. Vancouver, CA. April 15–21, 2016.
2017	Co-Chair, Review Movement Disorders Abstracts. 2017 AAN Annual Meeting. Boston, MA. April 21–27, 2017.
2017	<u>Co-Chair</u> , Scientific Platform Session. Beyond levodopa therapy
2018	<u>Co-Chair</u> , Review Movement Disorders Abstracts. 2018 AAN Annual Meeting. Los Angeles, CA. April 21–27, 2018. <u>Co-Chair</u> , Movement disorders S26 Movement Disorders: Parkinson's Disease Clinical Trials platform session 2018 AAN Annual Meeting. Los Angeles, CA. April 21–27, 2018.
2019	<u>Co-Chair</u> , Review Movement Disorders Abstracts. 2019 AAN Annual Meeting. Philadelphia, PA. May 4-7, 2019. <u>Co-Chair</u> , Movement disorders S26 Movement Disorders: Parkinson's Disease Clinical Trials platform session 2019 AAN Annual Meeting. Philadelphia, PA. May 4-7, 2019.
2019-	Fellow, American Academy of Neurology (FAAN)

American Neurological Association

2009 - Elected member
2010, 2011, 2014 Abstracts reviewer for the annual meeting
2010, 2011, 2014 Co-Chair, Scientific Platform Session. Therapeutics Parkinson's Disease
2015- Editorial Board, Annals of Clinical and Translational Neurology
2015- Member Interactive lunch workshop Planning Committee annual ANA meeting
2017 Invited speaker. Leader in the field presentation. Special Interest Group (SIG) Symposia
Non motor PD. ANA annual meeting, San Diego October 2017

Movement Disorder Society (1996-)

2007 Visiting Professorship, Chile
2008 Local Planning Committee for the 12th International Movement Disorders Society Congress
2014- Member Awards Committee
2012- Member, Educational Committee (Travel grants)
2015 Abstracts Reviewer
2017- Member, Non motor working group
2017-2018 Co-Chair. Awards Committee. International Parkinson and Movement Disorder Society (MDS).
June 30, 2017-September 30, 2019.
2018- Member, Task Force, PD subtypes
2019-2021 Chair. Awards Committee. International Parkinson and Movement Disorder Society (MDS).
2017-2021 Member, Executive Steering Committee, Pan American Section
2019- Co-Founder , Task Force, Clinical genetic testing in Parkinson's disease
2019- 2021 LEAP Mentor
2020, 2021 Co-Director. MDS-PAS annual Movement Disorders School for Neurology residents
2021- Member, Executive Steering Committee, International Parkinson and Movement Disorder Society (MDS).
2021- Member, PD Subtypes Task Force, International Parkinson and Movement Disorder Society (MDS).

Parkinson Study Group (PSG)

2006 -09 Annual Symposium Organization Committee
2007- Cognitive Study Group PSG
2008- Motor manifestations Study Group PSG
2011 Co-Chair, Motor manifestations Study Group PSG
2012- 2015 Chair, Motor manifestations Study Group PSG
2014- 2016 Credentials Committee
2013- Principal investigator, 3 national PSG studies
2020- Member, PSG Steering Committee

Parkinson's Foundation (PF)

2005 Symposium Organization Committee
2009- 2015 Steering committee Quality Improvement Initiative
2018- Steering committee PF Genetic Initiative

International Association Parkinsonism and Related Disorders (IAPRD)

2010- Elected member
2012 Course Director. Visiting Professorship. Parkinson's disease and other movement disorders.
Tanzania. Sponsored by WFN (February 2012)

2017 Invited speaker and session Co-Chair
 2017 Member, Scientific Program executive committee for the 2018 Congress (Lyon)
 2018-2019 **Chair**, Scientific Program executive committee for the 2019 Congress (Montreal)
 2019-2020 Member, Scientific Program executive committee for the 2020 Congress (virtual)
 2021- Member, Scientific Program executive committee for the 2022 / 2023 Congress

Parkinson's World Congress

2009 Abstracts reviewer for the annual International Association for Parkinsonism and Related Disorders
 2012 Member, Educational Committee
 2015, 2017, 2019 Invited Speaker
 2019- Chair, Fundraising committee
 2021 Invited Speaker

Michael J Fox Foundation

2016-2017 MJFF. Executive Scientific Advisory Board Member (ESAB)
 2018- MJFF Therapeutic Pipeline Program (TPP) Advisory Committee
 2016-2022 MJFF Therapeutic Pipeline Program (TPP) grants reviewer (5 year commitment, 2 cycles/ year)
 2021- MJFF. Adviser regarding grants policy and procedures on Diversity, Equity and Inclusion
 2022- MJFF Advisory Panel, Clinical outcomes assessments, Chair

Data and Safety Monitoring Board (DSMB)

2022- Member, Neurocrine

PROFESSIONAL and SCIENTIFIC SERVICE

2004-2009 Data Safety Monitoring Board. Study of efficacy and safety of cortical stimulation for patients with essential tremor. Northstar.
 2006 -2009 Data Safety Monitoring Board. Study of efficacy and safety of cortical stimulation for patients with depression. Northstar.
 2006- Medical Adviser. Parkinson Alliance IL
 2006-2010 Member of the Executive Educational Committee. We Move Online educational and CME website on movement disorders. Supervised design of the resident's online movement disorders educational curriculum.
 2007-2010 Steering Committee. PRAMIBID MultiCenter Clinical Trial. PSG
 2010- 2015 Steering Committee NIH NET-PD study (Neuroprotective initiative in Parkinson's disease)
 2009- 2015 Steering Committee. National Parkinson Foundation. Quality improvement initiative.
 2011- Steering Committee. Parkinson's Progression Biomarker Initiative study (PPMI). Sponsored by the MJFF
 2013- Steering Committee. STEADY-PD III – Study Principal Investigator , Steering Committee
 2013-2015 Steering Committee. FS-ZONE Study Principal Investigator, Steering Committee
 2014-2015 NEC Executive Committee. Neuro NEXT NINDS Consortium
 2017- Data Safety Monitoring Board. An Open-label Safety and Efficacy Study of VY-AADC01. Voyager.
 2018- Steering Committee. AT HOME PD – Study Co-Principal Investigator, Steering Committee
 2019- Executive Steering Committee (one of four co- leaders). Parkinson's Progression Biomarker Initiative study (PPMI 2.0). Sponsored by the MJFF
 2018- Scientific Advisory Committee Sanofi US Services Inc.
 Multicenter, Randomized, Double-Blind, Placebo Controlled Study of GZ/SAR402671 in Patients with

- 2018- Early-Stage Parkinson's Disease Carrying a GBA Mutation
Scientific Advisory Committee NeuroDerm, Ltd.
Prot# ND0612H-012, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinson's Disease
- 2021-2022 4D Pharma. Steering Committee. The First In Human Trial of MRx0029 and MRx0005 in patients with Parkinson's Disease
- 2021- Coordinating National Principal Investigator. PD0053 Orchestra trial UCB
- 2021- Coordinating National Principal Investigator. PADOVA trial, Roche
- 2021- Critical Path Parkinson's Consortium (Government Industry partnership on development of standardized approaches to clinical trials . Adviser
- 2021- NINDS Common data Elements (CDE) Parkinson's Disease v2.0 Working Group **Co-Chair**

Grants Reviewer

National, International

- 2008- 2009 Reviewer, Grants, **Research Grants Council**, Hong Kong, China
- 2008 **NIH** Member Conflict Special Emphasis Panel. Grants Reviewer October and June 2008
- 2009 **NIH** Member Conflict Special Emphasis Panel. Grants Reviewer; February 2009
- 2011 **NIH** Member Conflict Special Emphasis Panel. Grants Reviewer; June 2011 review cycle.
- 2009- 2011 Reviewer, Grants, **MJFF**
- 2012 Chair, Review committee, The Edmond J. Safra Core Programs for PD Research Grants, **MJFF**
- 2012 Reviewer. **National Institute of Health** SBIR Review. March.
- 2012 Ad Hoc reviewer panel SBIR applications of an **NIBIB** RFA entitled "Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44])."
- 2013 Ad Hoc reviewer panel SBIR applications of an **NIBIB** RFA entitled ETTN-10 Small Business Review Panel, CSR, NIH
- 2014 Reviewer, SBIR applications for an **NIH** RFA entitled "Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44])." September 18, 2014.
- 2015-2016 Reviewer, Grants, **MJFF**
- 2015 Committee Member. 3rd **Annual International Conference on Neurosciences and Neurobiology Research** (CNN 2015). Bangkok, Thailand. October 26-27, 2015.
- 2016 **NIH** Center for Scientific Review 201605 CNN Study Section. February 3-4, 2016. San Francisco, CA
- 2016 **NIH** Reviewer. 2016/08 ZNS1 SRB-T (20). Biomarkers for Lewy Body Dementias
- 2016 **NIH** Reviewer. 2016/10 ZNS1 SRB-T (18). Parkinson's Disease Biomarker Program Discovery Projects
- 2017- Present Reviewer, Grants, **MJFF**. Therapeutic Pipeline Program
- 2018-Present Review Section, **Department of Defense**, Parkinson's research program, PRP initiative (Annually)
- 2021 Reviewer, **National Institute of Neurological Disorders and Stroke**, **Udall Centers of Excellence** Award

Institutional, Local

- 2010-2014 Reviewer, Paul Ruby Foundation for Parkinson's Research Grants Initiative
- 2015-2017 Chair, Paul Ruby Foundation for Parkinson's Research Grants Initiative
- 2011- Chair, Parkinson's Disease Advisory Council Grants Initiative, NU FSM
- 2015- 2017 Reviewer. Northwestern University Clinical and Translational Sciences Institute (NUCATS) Multidisciplinary Mentored Career Development Program (KL2) Program. Northwestern University. Chicago, IL.
- 2014, 2015, Reviewer, Dixon Translational Research Grant Initiative, NU FSM
- 2017, 2018, 2019
- 2022 Reviewer NUCATS COVID junior investigator awards

Editorial Boards

2015- Annals of Clinical Translational Neurology (ACTN) journal, ANA
 2017- Associate editor, Movement Disorders
 2018- Associate editor. Parkinsonism and related disorders
 2018- **Invited editor**, Current Neurology and neuroscience reports, Movement disorders section
 2018- **Invited editor**, Journal of Parkinson's Disease, Clinical Trials Corner (3 publications / year)

Ad Hoc Manuscript reviewer

Annals of Neurology, European Journal of Neurology, Expert Review of Clinical Pharmacology, Frontiers in Bioscience, Future Neurology, JAMA Neurology, Journal Neuroscience, Journal of Clinical Investigation, Journal Parkinson Disease, Lancet Neurology, MEDSCAPE, Mount Sinai Review, Movement Disorders, Neurodegenerative Disease Management, Neurology, Neurotherapeutics, New England Journal of Medicine, Oxford Academic: Brain, Parkinsonism and Related Disorders, Science Translational Medicine, Thomson Reuters' Drug Profiles, Up to Date

TEACHING EXPERIENCE (selected)

Ongoing:

2001-2014 Responsible for the Core Educational curriculum for the Neurology residents
 2000 - 2015 Annual Lecture on Movement Disorders for the Neurology residents as part of the Neurology Basic Science lecture curriculum
 2000 - 2007 Annual Lecture on Movement Disorders for the NUIN graduate students class as part of the lecture curriculum
 2001-2013 Annual Lecture on Movement Disorders for the M2 class as part of the Neurology lecture curriculum
 2001-2013 Annual Lecture on Movement Disorders for the geriatric fellows as part of the lecture curriculum
 2001-2013 Annual Lecture on Movement Disorders for the geriatric psychiatry fellows as part of the lecture curriculum
 2013-2018 Annual Lecture on Movement Disorders for the school of physician assistants FSM as part of the lecture curriculum
 2013-2018 Annual Lecture on Movement Disorders research strategies for the school of physical therapy FSM as part of the research boot camp
 2001- Annual participation in the neurology core clerkship curriculum
 2006 - 2015 Course Director. National Association of Consulting Pharmacists. Management of Parkinson's disease and other movement disorders. Mini-fellowship (course given twice annually)
 2004 -2009 Course Co-Director. Annual Symposium on Parkinson's disease and Multiple Sclerosis for the residents. Attended by 20-30 residents from 6 states.
 2001- 2021 Program Chair. Annual patient education symposium on Parkinson's disease and other movement disorders (current attendance > 300 patients)
 2014- Director, Parkinson's Disease & Movement Disorders Center Seminar Series, Northwestern University Feinberg School of Medicine, Chicago, IL

Selected teaching activities and invited presentations (last 5 years):

International

2017 Invited Speaker, 12 Congress International Association for Parkinsonism and Related Disorders Ho Chi Minh City, Vietnam, Nov 12-15, 2017
 2018 Invited Speaker, ADPD satellite symposium. Biomarkers for PD clinical trials Torino, Italy, March 15-18th, 2018
 2018 Invited Speaker, Controversies in Neurology symposium. Is physiotherapy effective in functional movement disorders? Warsaw, Poland, March 21-24th, 2018
 2018 Invited Speaker ADPD 2018. Drug Development, Clinical Trials and Trial Design: aggregation inhibitors. AAT-AD/PD Focus Meeting Torino, Italy March 15, 2018
 2018 Invited Speaker CONy 2018 "Is physiotherapy helpful in functional motor disorders?" Warsaw, Poland. March 22-25, 2018/

- 2018 Invited Speaker CONy 2018 “Should PD Psychosis be treated early with antipsychotics?” Warsaw, Poland. March 22-25, 2018
- 2018 Invited Speaker MDS PAS Parkinson’s Disease Education Course “Disease-Modifying Treatments including Outcome Measures” and Symptomatic Treatments including Outcome” Miami, FL. June 21, 2018
- 2018 Invited Speaker 13 Congress International Association for Parkinsonism and Related Disorders. Platform. Disease modification in PD. Where do we stand. Lyon, France, August 19-22, 2018
- 2019 Invited Speaker Tel Aviv Medical Center “PPMI genetic non-manifest cohort: what can we learn?” Tel Aviv, Israel. March 19, 2019
- 2018-2019 Chair Scientific Congress Committee. 14 Congress International Association for Parkinsonism and Related Disorders. Montreal, June 2019
- 2019 Invited Speaker. Plenary session. Biomarkers in PD clinical trials. 14 Congress International Association for Parkinsonism and Related Disorders. Montreal, June 2019
- 2019 Invited Speaker. Digital technology in PD clinical trials. World Parkinson Congress (WPC). Kyoto, June 2019
- 2019 Invited Speaker. Antihypertensive agents in Parkinson’s disease: drug repurposing. International Movement Disorders Congress (MDS). Nice, September 2019
- 2020 Invited Speaker International Parkinson’s and Movement Disorder Society Virtual Congress 2020. September 13th 2020 “A new horizon: how will slowing disease progression in Huntington’s and Parkinson’s Disease transform patient care?” Sponsored symposium
- 2020 Invited Speaker International Parkinson’s and Movement Disorder Society Virtual Congress 2020. September 13th 2020 “Targeting α -synuclein to slow the progression of PD”. Sponsored symposium
- 2020 Invited Speaker International Parkinson’s and Movement Disorder Society Virtual Congress 2020. September 14th 2020. “Update on Recent Clinical Trials”. Parallel session
- 2020 Invited Speaker. AAN. Virtual. Science in the clinic. Late breaking poster presentation. NILO_PD study American Academy of Neurology, September 24th, 2020
- 2020 Invited Speaker ANA 2020 Annual Meeting, Virtual Meeting. October 9th 2020. “Clinical Genetic Testing for Parkinson’s Disease: What, When and How”
- 2020 Invited Speaker. “Clinical Genetic Testing for Parkinson’s: Are We There Yet” 2020 Annual Meeting American Academy of Neurology, April 26th, 2020 (cancelled)
- 2020 Invited Speaker. “The Future of Parkinson’s Disease: Genetic Targets and Emerging Therapeutic Pathways.” 2020 Annual Meeting American Academy of Neurology (Virtual)
- 2020 Invited Speaker. “PD Therapeutic Updates- What’s New?: Treatment of nonmotor symptoms”, XXV World Congress on Parkinson’s Disease and related Disorders 2020, June 8, 2020 (cancelled)
- 2020 Invited Speaker. “Is continuous dopaminergic stimulation better strategy than pulsatile in every patient?” The 14th World Congress on Controversies in Neurology, March 28th, 2020 (cancelled)
- 2021 Invited Speaker. “Parkinson’s Disease: Update on Recent Clinical Trials”. AAN 2021, Annual Meeting. April 19th, 2021 (virtual)
- 2021 Invited Speaker. “Drug repurposing: Nilotinib, Exenitide, Inosine”. MDS-PAS New and Emerging Therapies in Parkinson’s Disease and Other Movement. April 21st, 2021 (virtual)
- 2021 Invited Speaker. “What does the future hold to slow the disease?”. World Parkinson’s Congress 2021. May 17th, 2021 (virtual)
- 2021 Invited Speaker. “Parkinson’s Disease: Update on Recent Clinical Trials” Path to Prevention in Parkinson’s disease. April 8, 2021 (virtual)
- 2021 Invited Speaker. “Newest therapies update in Parkinson’s and Huntington’s disease” Movement Orders Today, Kiev, Ukraine (virtual). November 12, 2021
- 2021 Invited Speaker. “Predicting the progression of PD” 2021 International Conference of Korean Movement Disorder Society (virtual). December 10, 2021
- 2022 Invited Speaker. “GBA and LRRK2 targeting therapies: rationale and trial update”. International Parkinson and Movement Disorder Society Congress 2022. Prague, Czech Republic, May 1-4 2022.

- 2022 Invited Speaker. “Are we ready for PD prevention studies: PPMI experience.” McGill University Grand Rounds and Killiam Lecture Series. December 6th & 7th 2022. Montreal, Canada.
- 2023 Invited Speaker. “Are we ready for Parkinson's prevention studies.” Neurodegenerative Diseases Clinical Laboratory (National Institute of Neurology and Neurosurgery) Visit. February 8th 2023. Mexico City, Mexico.
- 2023 Invited Speaker. “Synuclein toxicity is the core (No) element of PD”. CONY, March 24th 2023. Dubrovnik, Croatia
- 2023 Invited Speaker. “Should RBD patients be told re PD risk”. CONY, March 24th 2023. Dubrovnik, Croatia
- 2023 Invited Speaker. “Are we ready for Parkinson's prevention studies?”. University of Toronto Grand Rounds. May 12th 2023. Toronto, Canada.
- 2023 Presenter. “Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design”. International Congress of Parkinson's Disease and Movement Disorders, August 28, 2023. Copenhagen, Sweden.
- 2023 Invited Speaker. “Becoming a Clinical Trialist: Establishing a Collaborative Partnership with Industry and Foundations”. International Congress of Parkinson's Disease and Movement Disorders, August 30, 2023. Copenhagen, Sweden.
- National (last 5 years)
- 2018 Co-Chair AAN 2018 Annual Meeting. “Movement Disorders: Parkinson’s Disease Clinical Trials” Los Angeles, CA. April 24, 2018.
- 2018 Invited Speaker MJFF Industry Summit – Trial Design for Disease Modification. “Standard Disease Progression Trials” New York City June 13, 2018
- 2018 Invited Speaker The Parkinson's Disease Education Course for Industry Professionals. “Disease-Modifying Treatments including Outcome Measures”. MDS-PAS. Miami, FL June 21, 2018
- 2018 Invited Speaker Sunovion Symposium at MDS-PAS “Treatment options and approaches for OFF states in Parkinson’s Disease” Miami, FL. June 22, 2018
- 2018 Invited Speaker IAPRD World Congress. Corporate Session. “Debating OFF Phenomenon in Parkinson’s Disease” Lyon, France August 19-22, 2018
- 2018 Invited Speaker Michael J. Fox Foundation (MJFF) Research Advocacy Meeting and Hill Day. Washington, DC Sept 12-13, 2018
- 2019 Invited Speaker Michael J. Fox Foundation (MJFF) LRRK2 Meeting. New York City April 25, 2019
Characteristics of the LRRK2 non manifest PPMI cohort
- 2019 Invited Speaker Michael J. Fox Foundation (MJFF) PPMI meeting. New York City May 1, 2019
Characteristics of the LRRK2 and GBA non manifest PPMI cohorts
- 2019 Invited Speaker Jane Wright Symposium “Pipeline of experimental therapeutics. Why PD community should be optimistic”. Philadelphia, Pennsylvania May 3, 2019
- 2019 Co-Chair AAN 2019 Annual Meeting. “Movement Disorders: Parkinson’s Disease Clinical Trials session” Philadelphia. May 5, 2019.
- 2019 Invited Speaker AAN 2019 Plenary session at the Annual Meeting. “Clinical Trials Highlights. STEADY –PD 3. Final study results” Philadelphia. May 7, 2019.
- 2019 Invited Speaker AAN 2019 Scientific session at the Annual Meeting. “Biomarkers PD” Abstract with distinction Philadelphia. May 8, 2019.
- 2019 Invited Speaker Michael J. Fox Foundation (MJFF) Therapeutic conference. “Drug repurposing: Hope versus Hype”. New York City October 15, 2019.
- 2019 Invited Speaker ACADIA Product Theater (title) Colorado Springs, November 7, 2019.
- 2020 Invited Speaker Penn State Grand Rounds. “Parkinson’s disease Quest for neuroprotection Past, present and future”. Philadelphia, PA January 2, 2020.
- 2020 Invited Speaker University of Iowa Grand Rounds. “Parkinson’s disease Quest for neuroprotection Past, present and future”. Iowa City January 7, 2020.

- 2020 Invited Speaker Cornell University Grand Rounds. “Parkinson’s disease Quest for neuroprotection. The story of 2 drugs”. New York City February 18, 2020.
- 2020 Invited Speaker University of California San Diego Grand Rounds. “Prodromal Parkinson’s Disease the Next Frontier”. San Diego April 16, 2020.
- 2020 Invited Speaker University of Rochester. Goldberg Family annual distinguished speaker Grand Rounds. “Disease modification Parkinson’s Disease the Nee Frontier”. Virtual, September 25, 2020.
- 2020 Moderator and co-director. Fifth Annual MDS-PAS Movement Disorders School for Neurology Residents, October 10, 2020 (virtual)
- 2021 Invited Speaker. “Convention vs. Innovation I: Time To Abandon Clinician-Administered Scales As The Primary Outcome Measure Of Symptomatic And Disease Modifying Trials In Parkinson Disease”, 8th Annual Shaping the Management of Parkinson’s Disease, January 23rd, 2021 (virtual)
- 2021 Invited Speaker. “Genetics in Movement Disorders Research and Care”. MJFF Edmond J. Safra Fellowship Webinar, March 25th, 2021 (virtual)
- 2021 Invited Speaker. “Prodromal Parkinson’s disease: Are we ready for prevention studies?” University of Alabama, Birmingham Grand Rounds. April 13th, 2021 (virtual)
- 2021 Invited Speaker. “Update in Movement Disorders 3”. American Academy of Neurology Annual Meeting. April 19th, 2021 (virtual)
- 2021 Invited Speaker. “Parkinson’s Disease and Other Movement Disorders: A Series, the session”. MDS-PAS New and Emerging Therapies. April 21, 2021
- 2021 Invited Speaker. “Repurposing Drugs & Immunotherapies”. XXVI World Congress on Parkinson's Disease and Related Disorders (Virtual). May 2nd, 2021.
- 2021 Invited Speaker. What does the future hold to slow the disease? World Parkinson’s Coalition Virtual Congress 2021. May 17th, 2021.
- 2021 Invited Speaker. “Impact of Functional Aspects of iPD and GBA-PD: Patient and Provider Perspectives Supporting Digital Endpoint Development”. European Academy of Neurology 2021, 7th Annual Congress. June 21st, 2021.
- 2021 Invited Speaker. “Promising clinical trials and emerging research in PD”. Ask the Doctor Series (Skypass Foundation). August 17th, 2021.
- 2021 Invited Speaker. “Defining LRRK2-PD subsets based on olfactory function in the PPMI”. International Parkinson and Movement Disorder Society Virtual Congress 2021. September 17-22nd, 2021.
- 2021 Invited Speaker. “Parkinson Progression Marker Initiative – New Science/New Cohorts”. International Parkinson and Movement Disorder Society Virtual Congress 2021. September 17-22nd, 2021.
- 2021 Invited Speaker. “Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease”. International Parkinson and Movement Disorder Society Virtual Congress 2021. September 17-22nd, 2021.
- 2021 Invited Speaker. “Emergence of new symptoms in experiences of daily living in early Parkinson’s disease”. International Parkinson and Movement Disorder Society Virtual Congress 2021. September 17-22nd, 2021.
- 2021 Invited Speaker. “Parkinson Disease Tomorrow: Evaluation of New Targets and Formulations” Inaugural Movement Disorder Summit (CME), October 30th, 2021.
- 2021 Invited Speaker. “Parkinson's disease modification trials- are we there yet?” Ohio State University Grand Rounds, November 2nd, 2021
- 2021 Invited Speaker. “Patient selection for alpha-synuclein therapeutic trials during a session on clinical trial design”, Michael J Fox Foundation Alpha-synuclein Therapeutics Summit, November 3rd, 2021.
- 2021 Invited Speaker & Host. “Parkinson’s Disease: Early, Middle and Advanced”, MDS-PAS 6th Annual Movement Disorders School for Neurology Residents. November 6th, 2021.
- 2021 Invited Speaker. “Pharmacotherapy and Parkinson's Disease and Dementia”. American College of Neuropsychopharmacology Annual Meeting 2021. December 6, 2021.
- 2021 Invited Speaker. “An Update on Parkinson’s Disease Psychosis and its treatment”. Virtual Winter Psychiatry Update Conference. December 9, 2021.

- 2022 Invited Speaker. “Prodromal LRRK2/GBA clinical and biomarker phenotypes”. LRRK2 & GBA in Parkinson’s Industry Summit. May 11, 2022
- 2022 Invited Speaker. “Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III”. 2022 Parkinson’s Study Group Annual Meeting. June 3-5th, 2022.
- 2022 Invited Speaker. “PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early-stage Parkinson’s disease)”. 2022 Parkinson’s Study Group Annual Meeting. June 3-5th, 2022.
- 2022 Invited Speaker. “Clinical trials of c-Abl inhibition in Parkinson’s”. 2022 Grand Challenges in Parkinson’s Disease. Virtual. September 28th, 2022.
- 2023 Invited Speaker. “Parkinson’s & Medications – What’s New”. 2023 Parkinson's Foundation Expert Briefing. Virtual. March 8th, 2023
- 2023 Invited Speaker. “Building a consensus conceptual model of meaningful symptoms and impacts in early Parkinson’s disease” and “Discussion of next steps for PD-ISS – near and long-term”. Michael J. Fox Foundation Staging Alignment Discussion. April 12th, 2023, Washington, DC.
- 2023 Invited Speaker. “A biological classification of Parkinson’s: an integrated staging system”. April 18th, 2023. Parkinsons Disease Staging Virtual Symposium.
- 2023 Invited Speaker. “A biological classification of Parkinson’s: an integrated staging system”. MDS Consensus Meeting, April 22nd, 2023. Atlanta, Georgia.
- 2023 Invited Speaker. “Parkinson's disease: What's in the Pipeline”. University of Florida Parkinson Symposium. May 13th, 2023, Gainesville, Florida.
- 2023 Invited Speaker. “The first biologic staging paradigm for Parkinson’s Disease”. Michael J. Fox Foundation: Molecular Biomarkers & Disease Subtyping Workshop 2023. June 13th, 2023, New York, New York.
- 2023 Invited Speaker. “Parkinson’s Disease: A biological definition and integrated staging system”. Denali Therapeutics Parkinson Disease Forum. August 15th, 2023 (virtual)
- 2023 Invited Speaker. “Neuronal Synuclein Disease: A biological definition and integrated staging system (NSD-ISS)”. LBDA Industry Advisory Council (IAC), September 14th, 2023 (virtual)
- 2023 Invited Speaker. “Path to prevention (P2P) trial : study design and status update”. Michael J. Fox Foundation 15th annual Parkinson's Disease Therapeutics Conference, October 19th, 2023, New York, New York.

Local (Selected last 5 years)

- 2017 Lecturer. CME “Parkinson's Disease: Physiological, Psychosocial, and Practical Rehabilitation Approaches.” Northwestern University, Marion Joy Hospital. Wheaton, IL. April 29, 2017.
- 2017 Program Chair and Speaker. CME program: latest update on movement disorders and dementias Northwestern Medicine, October 14, 2017.
- 2019 Invited Speaker. “New Frontiers in Research and Care.” Skokie, IL. June 29, 2019
- 2019 Program Speaker. CME program: latest update on movement disorders and dementias Northwestern Medicine, November 16, 2019.
- 2019 Grand rounds. “Prodromal Parkinson’s disease: does it exist?” Northwestern University. August 2019
- 2020 Program Speaker. “Overview of clinical phenotypes of genetic PD common mutations.” Northwestern Parkinson’s Disease Patient and Family Symposium. October 10, 2020
- 2021 Invited Speaker University of Chicago. “Clinical Genetic Testing in PD Are We Ready?” February 4, 2021
- 2021 CME Director, Northwestern University. Clinical Genetic Testing for Parkinson's Disease: Why, When and How? “Review of Genetically Targeted Therapeutics”. CME, Feb 25, 2021
- 2021 Invited Speaker. Edmond J. Safra Fellowship Webinar. “Genetics in Movement Disorders Research and Care”. April 25th, 2021
- 2021 Invited Speaker. Northwestern University. Botulinum Toxin Symposium. “Bleph/Hemifacial Spasm”.

September 15th, 2021.

2021 Invited Speaker. Northwestern University. Parkinson’s Disease Virtual Patient & Family Symposium. “Therapeutic Pipeline and Genetics in Early Parkinson’s Disease”. October 9th, 2021.

2021 Invited Speaker. “The Burgeoning Landscape for PD Therapy: An Update on Clinical Trials”, New Horizons in the Diagnosis and Management of Movement Disorders, Northwestern University Virtual CME, November 3, 2021.

2023 Invited Speaker. “Challenges in measuring clinical disease progression in PD: Lessons from PPMI and clinical trials”. World Congress on Parkinson’s Disease & Related Disorders. May 14th, 2023.

2023 Invited Speaker. “Challenges and opportunities in measuring clinical disease progression in PD lessons from PPMI and other trials”. World Parkinson’s Congress 2023, May 16th 2023. Chicago, IL.

MEDIA COVERAGE (Selected last 5 years)

Yahoo Website 04/03/2018
 The Michael J. Fox Foundation Launches "Parkinson's Clinical Trial Companion," Educational Suite Designed to Support Progress in Parkinson's Research by Increasing Patient Participation in Clinical Studies
<https://www.yahoo.com/news/michael-j-fox-foundation-launches-parkinsons-clinical-trial-140400801.html>

ForceBiotech Website 04/05/2018
 Pfizer, Acadia fund Fox Foundation’s new tool for Parkinson’s clinical studies
<https://www.fiercebiotech.com/cro/pfizer-acadia-fund-fox-foundation-s-new-tool-for-parkinson-s-clinical-studies>

NBC-5 Chicago Website 05/07/2018
 Man uses Parkinson’s diagnosis to achieve the improbable
<https://www.nbcchicago.com/on-air/as-seen-on/WEB-parkinsons-disease-walk-across-america-476177053.html>

News-Medical Website 08/02/2018
 New treatment may be on the horizon for Parkinson’s disease
<https://www.news-medical.net/news/20180802/New-treatment-may-be-on-the-horizon-for-Parkinsons-disease.aspx>

NeurologyLive Website 05/05/2019
 Isradipine Fails to Slow Early Parkinson Disease Progression in Phase 3 Study
<https://www.neurologylive.com/conferences/aan-2019/isradipine-fails-slow-early-parkinson-disease-progression-phase-3-study>

Reuters Health 11/19/2019
<https://www.medscape.com/viewarticle/921402>

Neurology Learning Online: Advances in Clinical Genetic Testing for Parkinson Disease 11/03/2020
<https://www.neurologylearningnetwork.com/qas/advances-clinical-genetic-testing-parkinson-disease>

Parkinsonism Related Disorders: Editorial 02/01/2023
[A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease](#)

TRAINEES (Selected last 10 years and restricted to the trainees who completed research projects)

Undergraduate Summer Students	
2011	Katherine Gordon
2011	Yekaterina Alnikova
2012	Ryan Brooks

2013	Alvin Singh
2013	Jared Weingart
2013	Abby Lagunov
2013-2014	Paulina Gonzalez Latapi
2015	Andrew Posen
2015	Mara Dubnow
2016	Tea Garibovic
2016	Matt Posen
Pre Medical Students	
	Michael Belmonte
	Danielle Tan
	Brad Schifrien
	Elise Johnson
	Tom Bielawiec
	Mehul Gilani
Residents	Roneil Malkani
2017	Adam Margolis
	Daniele Larson
2018	Adam Margolis
	Daniele Larson
	Paulina Gonzalez
	Margaret Yu
	Sean Shetty
2019	Ornella Dubaz
	Jennifer Smith
	Leonard Sokol
2020	Sarah Brooks
	Leonard Sokol
R25 trainees	
2012-2014	Daniela Menichella MDPHD
2015-	Tracey Gertler MDPHD
2016-	Jonathan Brent MDPHD
2017-	Neil Nadskarni MD
2018-	Divakar Mithal, MD PhD
2018-	Scott Adney MD PhD
2019	Behnam Sabayan, MD PhD
2020	Rafal Sobota
2020-	Lenard Sokol
2020-	Sarah Brooker
Clinical Fellows	
2010-2011	Roneil Malkani
2011-2013	Odinachi Oguh
2013-2014	Danny Bega
2014-2015	Mahesh Padmanaban
2015-2017	Yasaman Kianirad
2016-2017	Kenny Tan (Malasia)
2017-2019	Neha Prakash
2018-2020	Danielle Larson (NeuroNEXT fellow)

2019-2021	Neil Shetty (Safra Foundation fellow)
2019-2021	Niccolo Mencacci (Parkinson Foundation fellow)
2020-2022	Jennifer Smith Adrissi(NeuroNEXT fellow)
2021-2022	Behzad Elahi
2021-2023	Sushma Kola
2022-2023	Sarah M. Brooker
2022-2023	Ignacio Keller-Sarmiento
Postdocs	
2010-2011	Minji Wu
2014-2019	Miriam Rafferty
2015-2017	Ajay Kurani
2017	Tara Jones Thesis Committee
2017-2020	Jordan Mannis
International visiting scholars	
2019	Lucia Riccardi, MD PhD, Great Britain
2019-2022	Ignacio Sarmiento , MD , Italy

ONGOING RESEARCH SUPPORT

ACTIVE (dated reflect current fiscal year, most grants expand multiyear funding)

U24NS107213 NINDS Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials NeuroNEXT Role: Site Principal Investigator	07/01/2018 – 06/30/2024
R25 NS070695 NINDS Research Education Programs for Trainees in Neurology Role: Co-Principal Investigator (4 trainees)	07/01/2020 – 06/30/2025
U01NS107009 MGH/NINDS AT-HOME-PD (Assessing Tele-Health Over Multiyear Extensions of PD trials) Role: Principal Investigator (Multiple PIs)	07/01/2018 – 04/30/2024
MJFF-023420 The Michael J. Fox Foundation Assessment of the stability of the Alpha-Synuclein Role: Co-Investigator	09/01/2023 – 09/30/2024
MJFF15875 The Michael J. Fox Foundation Parkinson's Progressive Markers Initiative (Steering Committee) Role: Steering Committee Member	01/01/2015 – 03/31/2024

MJFF-024280 The Michael J. Fox Foundation PD Endpoints Advisory Committee Role: PI	06/01/2023 – 06/01/2024
MJFF-021980 The Michael J. Fox Foundation The Edmond Safra Fellowship training in movement disorders Role: Principal investigator, mentor for 2023-2025 fellow	04/01/2022 – 06/30/2025
PF-COE-125274 Parkinson's Foundation FY24 Center of Excellence Role: PI	12/01/2023 – 11/30/2024
Prot# BP39529 Roche/Syneos Health A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson's Disease with a 52 Week Blinded Extension (Pasadena) Role: PI	05/02/2017 – 05/02/2024
Prot: PRV-PD101 Prevail Therapeutics A Phase 1/2a Study to Evaluate the Safety of PR001A in Patients with Parkinson's Disease with at Least One GBA1 Mutation Role: PI	07/05/2019 – 07/05/2025
Prot#NLY01-PD-1 Neuraly/Rho Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson's Disease	08/11/2020 – 03/24/2024
Prot#N2H-01D0612 NeuroDerm, Ltd. Prot# ND0612H-012: A Multicenter, International, Open-Label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinson's Disease Role: Site PI	04/09/2016 – 09/26/2023
P-163-PO28000007864//R01AG059417 NIA Trial of Parkinson's And Zoledronic Acid (TOPAZ) Role: PI	10/14/2020 – 02/28/2025
MJFF-021084 Michael J. Fox Foundation for Parkinson's Research A novel digital endpoint for detecting symptom changes in vocal tremor and speech prosody associated with Parkinson's Disease Role: PI	01/01/2022 – 06/30/2024

MJFF-023383 08/10/2020 – 07/31/2033
Michael J. Fox Foundation for Parkinson's Research
Parkinson's Progression Markers Initiation (PPMI) 2.0
Role: PI

Completed grants: (last 7 years)

NIH
U01NS080818 04/01/2014 – 03/31/2022
NINDS
Clinical Coordination Center for STEADY-PD3
Role: Principal Investigator

5-3865/U01NS43128-11 12/01/2013 – 11/30/2016
NINDS/University of Rochester
Neuroprotection Studies in PD: A Coordinating Center
Role: Principal Investigator (National PI- FS-Zone Study)

U10NS077271 09/30/2011 – 06/30/2018
NINDS
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials
NeuroNEXT
Role: Principal Investigator

DOD
Grant Number: NA 07/27/2007 – 08/31/2013
Study sponsor: Department of Defense
Title: Parkinson's Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson's Disease
Role: Site Principal Investigator

Foundations
Agreement Signed 7/16/19 01/01/2019 – 12/31/2023
Parkinson's Foundation, Inc.
Generation Parkinson's Disease (PD Gene)
Award#417547G
Role: Principal Investigator and Steering Committee member

MJFF14535 03/16/2018 – 07/31/2023
The Michael J. Fox Foundation
Fox BioNet
Role: Principal investigator

DI-2019C2-17499 01/01/2022 – 06/30/2023
Patient-Centered Outcomes Research Institute
Supplemental Support for Champions of Palliative Care
Role: PI

PF-COE-PC-2215 07/01/2022 – 06/30/2023
Parkinson's Foundation, Inc.
Implementing Team-based Outpatient Palliative Care in Parkinson Foundation Centers of Excellence
Role: PI

14618 Michael J. Fox Foundation for Parkinson's Research The Parkinson's Progression Markers Initiative Role: PI	08/09/2010 – 09/30/2023
MJFF18240 The Michael J. Fox Foundation Fox Genetic Network Role: Principal Investigator	05/01/2019 – 07/31/2022
University of Rochester WATCH PD Role: Site Principal Investigator	04/01/2019 – 05/31/2022
Paul Ruby Foundation for Parkinson's Research Northwestern University Parkinson's Disease and Movement Disorders Center Biorepository Role: Principal Investigator	01/01/2015 – 12/31/2016
Industry Prot# 228PD201 Biogen/IQVIA A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease Role: Site PI	09/01/2017 – 12/31/2022
Protocol #PD0004 UCB Biosciences, Inc. /Pharmaceutical Research Associates A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease Associated Pain Role: Co-Investigator	01/30/2013 – 01/30/2015
TVP-1012/PM106 INC Research, Inc./Teva Neuroscience, Inc. A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition on Patients with Parkinson's Disease Role: Principal Investigator	12/14/2012 – 01/13/2015
S187.3.005 Solvay Pharmaceutical, Inc./Quintiles, Inc. Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Role: Co-Investigator	02/01/2010 – 1/31/2016
SYN120-CL03 Biotie Therapies, Inc./MGH Efficacy of a fixed dose of SYN120 on cognition as determined by the Cognitive Drug Research Computerized Cognition Battery (CDR) Continuity of Attention in patients with PDD treated with a stable dose of a cholinesterase inhibitor. Role: site PI	01/01/2015 – 01/01/2018

SD-809 C-18 10/07/2014 – 10/07/2017
Auspex Pharmaceuticals, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Role: Site Investigator

CVT-301 01/05/2015 – 01/05/2018
Civitas Therapeutics, Inc/INC Research, LLC
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Role: Sub-I

Prot#ND0612H-006 09/01/2016 – 09/26/2019
Neuroderm, Ltd.
A Multicenter, Parallel-Group, Rater-Blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered via a Pump System as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinson's Disease
Role: Principal Investigator

Study No. 16779A 04/05/2016 – 07/06/2019
H. Lundbeck A/S
Interventional, Open-Label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral doses of Lu AE04621 in Patients with Parkinson's Disease
Role: Principal Investigator

Agreement 12763 08/16/2016 – 08/15/2018
The Michael J. Fox Foundation
Clinician-Input Study: How the Fox Insight Mobile Application Can Influence Treatment and Care
Role: National Principal investigator (4 sites)

Agreement 4/24/17 03/01/2017 – 12/31/2020
The Michael J. Fox Foundation
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson's Disease (PD)
Role: National Principal Investigator (25 sites)

Bibliography:

Original Papers:

1. **Simuni T**, Stern MB Diagnosis and Epidemiology of Parkinson's Disease: CNS Spectrum 1998; vol 3, No 2:23-35.
2. Colcher A, **Simuni, T**. Clinical Manifestations of Parkinson's Disease. Medical Clinics of North America. 1999; 83(2): 327-348. PMID: 10093581.
3. **Simuni T.**, Stern MB. Does Levodopa Accelerate Parkinson's disease? Drugs and Aging; 1999; 14: 399-408. PMID: 10408939.
4. **Simuni T**, Stern MB. Questions physicians commonly ask about treating Parkinson's disease. Consultant 1999; 39(2): 367-381.

5. Alterman RL, Reiter GT, Shils J, Skolnick B, Arle JE, Lesutis M, **Simuni T**, Colcher A, Stern M, Hurtig H. Targeting for thalamic deep brain stimulator implantation without computer guidance: assessment of targeting accuracy. *Stereotact Funct Neurosurg*. 1999;72(2-4):150-3. PMID: 10853070.
6. Telfeian AE, Boockvar JA, **Simuni T**, Jaggi J, Skolnick B, Baltuch GH. Efficacy of unilateral deep brain stimulation of the thalamic ventralis intermedius nucleus in a patient with bipolar disorder associated with Klinefelter syndrome and essential tremor. Case report. *J Neurosurg*. 2000 Jul;93(1):127-8. PMID: 10883915.
7. Boockvar JA, Telfeian A, Baltuch GH, Skolnick B, **Simuni T**, Stern M, Schmidt ML, Trojanowski JQ. Long-term deep brain stimulation in a patient with essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral thalamus. Case report. *J Neurosurg*. 2000 Jul;93(1):140-4. PMID: 10883919.
8. Alterman, R. L., G. T. Reiter, **Simuni T**. "Targeting for thalamic deep brain stimulator implantation without computer guidance: assessment of targeting accuracy." *Stereotact Funct Neurosurg* 1999;72(2-4): 150-3.
9. Schwalb, J. M., H. A. Riina, **Simuni T**, et al. Revision of deep brain stimulator for tremor. Technical note. *J Neurosurg* 2001 Jun; 94(6): 1010-2. PMID: 11409503.
10. Colcher A, **Simuni T**. Other Parkinson syndromes. *Neurol Clin* 2001 Aug;19(3): 629-49,vii. PMID: 11532467.
11. **Simuni T**, MD, Jurg L. Jaggi, PhD, et al. Bilateral Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Study of Efficacy and Safety. *J Neurosurgery* . April 2002; 96(4); 666-72. PMID: 11990805.
12. Counelis GJ, **Simuni T**, Forman MS, et al. Bilateral subthalamic nucleus stimulation for advanced Parkinson's disease: correlation of intraoperative MER and postoperative MRI with neuropathological findings. *Mov Disord*. 2003; 18: 1062-1065. PMID: 14502679.
13. **Simuni T**. Somnolence and other sleep disorders in Parkinson's disease: the challenge for the practicing neurologist. *Neurol Clin*. 2004 Oct;22(3 Suppl):S107-26. PMID: 15501360.
14. Curtin KR, Shaibani A, Resnick SA, Russell EJ, **Simuni T**. Rheolytic catheter thrombectomy, balloon angioplasty, and direct recombinant tissue plasminogen activator thrombolysis of dural sinus thrombosis with preexisting hemorrhagic infarctions. *AJNR Am J Neuroradiol*. 2004 Nov-Dec;25(10):1807-11. PMID: 15569752.
15. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez H, Trieschmann MM, Reichwein S, and **Simuni T**. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. *J Neurol Neurosurg Psychiatry*. 2005 Jul;76(7):934-9. PMID: 15965198.
16. MacKinnon CD, Gilley EA, Weis-McNulty A, **Simuni T**. Pathways mediating abnormal intracortical inhibition in Parkinson's disease. *Ann Neurol*. 2005 Oct;58(4):516-24. PMID: 16178015
17. Videnovic A, Semenov I, Chua-Adajar R, **Simuni T**, Raizer J. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. *Neurology*. 2005 Dec 13;65(11):1792-4. PMID: 16237130.
18. Siderowf A, Jaggi J, Xie, **Simuni T**, Baltuch G. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. *Mov Disord*. 2006 Jun;21(6):746-53. PMID: 16463342.
19. Liang, Chou, Baltuch, **Simuni T**, Siderowf A. Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease. *Stereotact Funct Neurosurg*. 2006;84(5-6):221-7. PMID: 17063034.
20. Mille ML, Johnson Hilliard, Martinez, **Simuni T**, Rogers. Acute effects of a lateral postural assist on voluntary step initiation in patients with Parkinson's disease. *Mov Disord*. 2007 Jan;22(1):20-7. PMID: 17089421.
21. Videnovic A, **Simuni T**. Managing sleep disorders in Parkinson's disease. *Aging Health*, Feb 2007, vol 3, 1, PP 49-66.
22. Page DB, Weaver F, Wilkie DJ, **Simuni T**. A computerized survey of pain in Parkinson's disease patients: A pilot feasibility study. *Parkinsonism Relat Disord*. 2009. PMID: 19640770.
23. **Simuni T**, Sethi K. Nonmotor manifestations of Parkinson's disease. *Ann Neurol*. 2008;64 Suppl 2:S65-80. PMID: 19127582.
24. **Simuni T**, Lyons, KE, Rajesh Pahwa R et al. Treatment of Early Parkinson's disease. Part I. *Eur Neurol* 2009;61(4):193-205. PMID: 19176960.

25. **Simuni T**, Lyons, KE, Rajesh Pahwa R et al. Treatment of Early Parkinson's disease. Part II. *Eur Neurol* 2009;61(4): 206-215. PMID: 19176961.
26. Mille ML, Hilliard MJ, Martinez KM, **Simuni T**, Zhang Y, Rogers MW. Short-term effects of posture-assisted step training on rapid step initiation in Parkinson's disease. *J Neurol Phys Ther.* 2009 Jun;33(2):88-95. PMID: 19556917.
27. Stegemoller EL, **Simuni T**, MacKinnon C. Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. *Mov Disord.* 2009 Jun 15;24(8):1162-9. PMID: 19412952.
28. Stegemoller EL, **Simuni T**, Mackinnon CD. The effects of Parkinson's disease and age on syncoated finger movements. *Brain Res.* 2009;1290:12-20. PMID: 19596277.
29. Stegemoller EL, **Simuni T**, Mackinnon CD. Reply: Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. *Mov Disord.* 2010. PMID: 19412952.
30. Page DB, Weaver F, Wilkie DJ, **Simuni T**. A computerized survey of pain in Parkinson's disease patients: A pilot feasibility study. *Parkinsonism Relat Disord.* 2010 Feb;16(2):139-41. PMID: 19640770.
31. Stegemoller EL, Allen DP, **Simuni T**, MacKinnon CD. Rate-dependent impairments in repetitive finger movements in patients with Parkinson's disease are not due to peripheral fatigue. *Neurosci Lett.* 2010 Sep 20;485(1):1-6. PMID: 20599591.
32. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, **Simuni T**, Troster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Working Group. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. *Mov Disord.* 2010 Nov 15;25(15):2501-7. PMID: 20878991.
33. Okun MS, Siderowf A, Nutt JG, O'Connor GT, Bloem BR, Olmstead EM, Guttman M, **Simuni T**, Cheng E, Cohen EV, Parashos S, Marsh L, Malaty IA, Giladi N, Schmidt P, Oberdorf J. Piloting the NPF data-driven quality improvement initiative. *Parkinsonism Related Disord.* 2010 Sep;16(8):517-21. PMID: 20609611.
34. Rogers RW, Hilliard MJ, Martinez KM, Zhang Y, **Simuni T**, Millie ML. Perturbations of ground support alter posture and locomotion couple during step initiation in Parkinson's disease. *Exp Brain Res.* 2010 Dec 12. PMID: 21153725.
35. **Simuni T**, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, Videnovic A, Weaver FM, Williams K, Surmeier DJ. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. *Mov Disord.* 2010 Dec 15;25(16):2863-6. PMID: 20818667.
36. Kuhta T, Zadikoff C, **Simuni T**, Martel A, Williams K, Videnovic A. Brain donation - What do patients with movement disorders know and how do they feel about it? *Parkinsonism Relat Disord.* 2011. PMID: 21220205.
37. Rogers MW, Kennedy R, Palmer S, Reising M, Martinez KM, **Simuni T**, Zhang Y, MacKinnon CD. Postural preparation prior to stepping in patients with Parkinson's disease. *J Neurophysiol.* 2011 Apr 27. PMID 21525376.
38. Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, **Simuni T**, Sutton J, Tuite P, Weintraub D, Zesiewicz, Clinical Vignettes in Parkinson's disease: A collection of unusual medication-induced hallucinations, delusions, and compulsive behaviors. *Int J Neurosci.* 2011 Jun 10. PMID: 21663381.
39. Cummings JL, Henchcliffe C, Schaier S, **Simuni T**, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. *Brain* 2011 Nov; 134(Pt 11):3146-66. Epub 2011 Aug 2. Review. PMID: 21810889
40. Malkani RG, Dickson DW, **Simuni T**. Hippocampal-sparing Alzheimer's disease as corticobasal syndrome. *Parkinsonism Relat Disord.* 2012 Jun;18(5):683-5. Epub 2011 Dec 14. PMID: 22172552.
41. Barsuk JH, Cohen ER, Caprio T, McGaghie WC, **Simuni T**, Wayne DB. Simulation-based education with mastery learning improves residents' lumbar puncture skills. *Neurology.* 2012 Jul 10;79(2):132-7. Epub 2012 Jun 6. PMID: 22675080.
42. Weaver FM, Stroupe KT, Cao L, Holloway RG, Vickrey BG, **Simuni T**, Hendricks A, Ippolito D. Parkinson's disease medication use and costs following deep brain stimulation. *Mov Disord.* 2012 Sep 15;27(11):1398-403. Epub 2012 Sep 13. PMID: 22975928.

43. Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, **Simuni T**. Amantadine for freezing of gait in patients with Parkinson disease. *Clin Neuropharmacol*. 2012 Nov-Dec;35(6):266-8. PMID: 23123688.
44. Creath RA, Prettyman M, Shulman L, Hilliard M, Martinez K, Mackinnon CD, Mille ML, **Simuni T**, Zhang J, Rogers MW. Self-triggered assistive stimulus training improves step initiation in persons with Parkinson's disease. *J Neuroeng Rehabil*. 2013 Jan 30;10:11. PMID: 23363975.
45. **Simuni T**, Brundin, P. J Parkinsons Dis. Is Exenatide the Next Big Thing in Parkinson's Disease? 2014 Apr 18. DOI 10.3233/JPD-149001.
46. Bega D, Wu SS, Pei Q, Schmidt PN, **Simuni T**. Recognition and Treatment of Depressive Symptoms in Parkinson's Disease: The NPF Dataset. *J Parkinsons Dis*. 2014 Jul 17. [Epub ahead of print] PMID: 25035310.
47. Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, **Simuni T**. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? *Neuro-degenerative diseases* 2015. PMID: 25592727 DOI: 10.1159/000370116
48. Carta AR, **Simuni T**. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. *Expert opinion on investigational drugs* 2015;24:219-227.
49. Lamotte G, Rafferty MR, Prodoehl J, et al. Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review. *Journal of Parkinson's disease* 2015;5:21-41.
50. Weintraub D, **Simuni T**, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society* 2015.
51. Writing Group for the NET-PD, Kieburtz K, Tilley BC, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. *Jama* 2015;313:584-593.
52. Stegemöller EL, Allen DP, **Simuni T**, MacKinnon CD. Motor cortical oscillations are abnormally suppressed during repetitive movement in patients with Parkinson's disease.. *Clin Neurophysiol*. 2015 May 29
53. **Simuni T**, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, Marek K; PPMI Sleep Working group on behalf of the PPMI Investigators. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. *Mov Disord*. 2015 Jun 11.
54. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. (**Simuni- PI**). Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. *The Lancet Neurology*. Published Online: 23 June 2015 [formal citation needed. not in pubmed yet]
55. Weintraub D, **Simuni T**, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Parkinson's Progression Markers I. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2015;30(7):919-27. doi: 10.1002/mds.26170. PubMed PMID: 25737166.
56. **Simuni T**, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K, Investigators P. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? *Parkinsonism & related disorders*. 2016. doi: 10.1016/j.parkreldis.2016.04.027. PubMed PMID: 27132498.
57. Chahine LM, Xie SX, **Simuni T**, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, Weintraub D. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. *Parkinsonism & related disorders*. 2016;27:102-6. doi: 10.1016/j.parkreldis.2016.03.006. PubMed PMID: 27010070.
58. Nowinski CJ, Siderowf A, **Simuni T**, Wortman C, Moy C, Cella D. Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2016;31(5):725-33. doi: 10.1002/mds.26546. PubMed PMID: 26919664.
59. Kianirad Y, **Simuni T**. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. *Current neurology and neuroscience reports*. 2016;16(4):34. doi: 10.1007/s11910-016-0635-8. PubMed PMID: 26898686.
60. Stegemoller EL, Allen DP, **Simuni T**, MacKinnon CD. Motor cortical oscillations are abnormally suppressed during repetitive movement in patients with Parkinson's disease. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2016;127(1):664-74. doi: 10.1016/j.clinph.2015.05.014. PubMed PMID: 26089232.

61. Neuro-QoL Health-related Quality of Life Measurement System: Validation in Parkinson's Disease
62. Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell D, Christine C, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, **Simuni T**, on behalf of the NET-PD LS-1 Investigators. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. *Movement Disorders Clinical Practice*. 2015; 2(4):371-378. DOI: 10.1002/mdc3.12205.
63. Bega D, Stein J, Zadikoff C, **Simuni T**, Victorson D, Ring M, Jovanovic B, Corcos D. Yoga Versus Resistance Training in Mild to Moderate Severity Parkinson's Disease: A 12-Week Pilot Study. *J Yoga Phys Ther*. 2016; 6:222. DOI:10.4172/2157-7595.1000222.
64. Bega D, **Simuni T**, Okun M, Chen X, Schmidt P. Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of Excellence. *Movement Disorders Clinical Practice*. 2016; In Press.
65. Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, **Simuni T**, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S, Movement Disorders Society Task Force on T. Technology in Parkinson's disease: Challenges and opportunities. *Movement disorders : official journal of the Movement Disorder Society*. 2016;31(9):1272-82. Epub 2016/04/30. doi: 10.1002/mds.26642. PubMed PMID: 27125836; PMCID: PMC5014594.
66. Rafferty MR, Schmidt PN, Luo ST, Li K, Marras C, Davis TL, Guttman M, Cubillos F, **Simuni T**; all NPF-QII Investigators. Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. *J Parkinsons Dis*. 2017;7(1):193-202. doi: 10.3233/JPD-160912. PMID: 27858719
67. Oustwani CS, Korutz AW, Lester MS, Kianirad Y, **Simuni T**, Hijaz TA. Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes? *Clin Imaging*. 2017 Jul-Aug;44:66-69. doi: 10.1016/j.clinimag.2017.04.005. Epub 2017 Apr 20. PMID: 28460362
68. Caspell-Garcia C, **Simuni T**, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson's Progression Markers Initiative (PPMI). Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. *PLoS One*. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017. PMID: 28520803.
69. Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, **Simuni T**; Parkinson's Progression Markers Initiative. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2017 Aug;88(8):653-662. doi: 10.1136/jnnp-2016-315023. Epub 2017 May 29. PMID: 28554959
70. Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, **Simuni T**; Parkinson Study Group STEADY-PD III Investigators. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). *Ann Clin Transl Neurol*. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun. PMID: 28589163
71. Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, **Simuni T**, Sterling M, Tariot P, Anderson KE. Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. *Patient*. 2017 Oct;10(5):541-544. doi: 10.1007/s40271-017-0257-5. PMID: 28688021
72. Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, **Simuni T**, Sterling M, Tariot P, Anderson KE. Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. *Patient*. 2017 Oct;10(5):667-668. doi: 10.1007/s40271-017-0271-7. PMID: 28766071

73. Surmeier DJ, Halliday GM, **Simuni T**. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. *Exp Neurol*. 2017 Dec;298(Pt B):202-209. doi: 10.1016/j.expneurol.2017.08.001. Epub 2017 Aug 2. PMID: 28780195
74. Kianirad Y, **Simuni T**. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. *Expert Rev Clin Pharmacol*. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17. PMID: 28817967
75. **Simuni T**, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kiebertz K, Chahine LM, Marek K. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. *J Neurol Neurosurg Psychiatry*. 2018 Jan;89(1):78-88. doi: 10.1136/jnnp-2017-316213. Epub 2017 Oct 6. PMID: 28986467
76. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, **Simuni T**, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. *Neurology*. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13. PMID: 29030452
77. Berk S, Greco BL, Biglan K, Kopil CM, Holloway RG, Meunier C, **Simuni T**. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial. *J Parkinsons Dis*. 2017;7(4):685-693. doi: 10.3233/JPD-171199. PMID: 29103052 Clinical Trial.
78. **Simuni T**, Kraine D. High priority publications on Parkinson's disease in 2017. *Lancet Neurol*. 2018 Jan;17(1):8-10. doi: 10.1016/S1474-4422(17)30416-7. Epub 2017 Dec 16. PMID: 29263010 No abstract available.
79. Chou KL, Stacy M, **Simuni T**, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? *Parkinsonism Relat Disord*. 2018 Jun;51:9-16. doi: 10.1016/j.parkreldis.2018.02.001. Epub 2018 Feb 2. PMID: 29456046 Review.
80. **Simuni T**, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kiebertz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. *Mov Disord*. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23. PMID: 29572948
81. Manes JL, Tjaden K, Parrish T, **Simuni T**, Roberts A, Greenlee JD, Corcos DM, Kurani AS. Altered resting-state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson's disease. *Brain Behav*. 2018 Sep;8(9):e01073. doi: 10.1002/brb3.1073. Epub 2018 Jul 25. PMID: 30047249
82. Margolius A, Cubillos F, He Y, Wu S, Schmidt P, **Simuni T**; NPF QII Investigators. Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. *Parkinsonism Relat Disord*. 2018 Nov;56:93-97. doi: 10.1016/j.parkreldis.2018.06.034. Epub 2018 Jul 2. PMID: 30056039
83. Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, **Simuni T**, Weintraub D; Parkinson's Progression Markers Initiative. Cognition among individuals along a spectrum of increased risk for Parkinson's disease. *PLoS One*. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018. PMID: 30125297
84. Sardi SP, **Simuni T**. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. *Parkinsonism Relat Disord*. 2019 Feb;59:32-38. doi: 10.1016/j.parkreldis.2018.10.025. Epub 2018 Oct 23. PMID: 30391183 Review.
85. Amara AW, Chahine L, Sedorff N, Caspell-Garcia CJ, Coffey C, **Simuni T**; Parkinson's Progression Markers Initiative. Self-reported physical activity levels and clinical progression in early Parkinson's disease. *Parkinsonism Relat Disord*. 2019 Apr;61:118-125. doi: 10.1016/j.parkreldis.2018.11.006. Epub 2018 Dec 10. PMID: 30554993
86. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, **Simuni T**; Parkinson's Progression Markers Initiative. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

- Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec. PMID: 30564614
87. Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, **Simuni T**, Morrissette DA, Stahl SM. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. *CNS Spectr*. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359. PMID: 30588905 Review.
 88. Chahine LM, Iranzo A, Fernández-Arcos A, **Simuni T**, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W; PPMI Sleep Working Group. Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. *NPJ Parkinsons Dis*. 2019 Jan 29;5:2. doi: 10.1038/s41531-018-0073-1. eCollection 2019. PMID: 30701189
 89. Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, **Simuni T**; Parkinson's Progression Markers Initiative, Steering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). *Parkinsonism Relat Disord*. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31. PMID: 30738748
 90. McFarthing K, **Simuni T**. Clinical Trial Highlights: Targetting Alpha-Synuclein. *J Parkinsons Dis*. 2019;9(1):5-16. doi: 10.3233/JPD-189004. PMID: 30741694 No abstract available.
 91. McFarthing K, **Simuni T**. Clinical Trial Highlights: Phase III Study in Spotlight. *J Parkinsons Dis*. 2019;9(1):3-4. doi: 10.3233/JPD-190002. PMID: 30741695 No abstract available.
 92. McFarthing K, Prakash N, **Simuni T**. Clinical Trial Highlights: 1. Gene Therapy for Parkinson's, 2. Phase 3 Study in Focus – Intec Pharma's Accordion Pill, 3. Clinical Trials Resources. *J Parkinsons Dis*. 2019;9(2):251-264. doi: 10.3233/JPD-199001. PMID: 31127735 No abstract available.
 93. Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, **Simuni T**, Morrissette DA, Stahl SM. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. *CNS Spectr*. 2019 Oct;24(5):574-575. doi: 10.1017/S1092852919000932. PMID: 31182180 No abstract available.
 94. Lonini L, Dai A, Shawen N, **Simuni T**, Poon C, Shimanovich L, Daeschler M, Ghaffari R, Rogers JA, Jayaraman A. Wearable sensors for Parkinson's disease: which data are worth collecting for training symptom detection models. *NPJ Digit Med*. 2018 Nov 23;1:64. doi: 10.1038/s41746-018-0071-z. eCollection 2018. PMID: 31304341
 95. McFarthing K, Prakash N, **Simuni T**. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. *J Parkinsons Dis*. 2019;9(3):449-465. doi: 10.3233/JPD-199002. PMID: 31356217 Review. No abstract available.
 96. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, **Simuni T**, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D; PPMI study. Longitudinal analyses of cerebrospinal fluid α -Synuclein in prodromal and early Parkinson's disease. *Mov Disord*. 2019 Sep;34(9):1354-1364. doi: 10.1002/mds.27806. Epub 2019 Jul 30. PMID: 31361367
 97. Mitchell T, Archer DB, Chu WT, Coombes SA, Lai S, Wilkes BJ, McFarland NR, Okun MS, Black ML, Herschel E, **Simuni T**, Comella C, Xie T, Li H, Parrish TB, Kurani AS, Corcos DM, Vaillancourt DE. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. *Hum Brain Mapp*. 2019 Dec 1;40(17):5094-5107. doi: 10.1002/hbm.24760. Epub 2019 Aug 12. PMID: 31403737
 98. Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, **Simuni T**, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K; The Parkinson's Progression Markers Initiative. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. *J Parkinsons Dis*. 2019;9(4):665-679. doi: 10.3233/JPD-181518. PMID: 31450510

99. Archer DB, Bricker JT, Chu WT, Burciu RG, McCracken JL, Lai S, Coombes SA, Fang R, Barmpoutis A, Corcos DM, Kurani AS, Mitchell T, Black ML, Herschel E, **Simuni T**, Parrish TB, Comella C, Xie T, Seppi K, Bohnen NI, Müller ML, Albin RL, Krismer F, Du G, Lewis MM, Huang X, Li H, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. *Lancet Digit Health*. 2019 Sep;1(5):e222-e231. doi: 10.1016/S2589-7500(19)30105-0. Epub 2019 Aug 27. PMID: 33323270
100. Rafferty MR, MacDonald J, Byskosh A, Sloan L, Toledo S, Marciniak C, **Simuni T**. Using Implementation Frameworks to Provide Proactive Physical Therapy for People With Parkinson Disease: Case Report. *Phys Ther*. 2019 Dec 16;99(12):1644-1655. doi: 10.1093/ptj/pzz129. PMID: 31508801
101. Elm JJ, Daeschler M, Bataille L, Schneider R, Amara A, Espay AJ, Afek M, Admati C, Teklehaimanot A, **Simuni T**. Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinson's disease data. *NPJ Digit Med*. 2019 Sep 25;2:95. doi: 10.1038/s41746-019-0169-y. eCollection 2019. PMID: 31583283
102. **Simuni T**, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kiebertz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurol*. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31. PMID: 31678032
103. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, **Simuni T**, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. *Genet Med*. 2020 Mar;22(3):574-580. doi: 10.1038/s41436-019-0684-x. Epub 2019 Nov 4. PMID: 31680121
104. Dubaz OM, Wu S, Cubillos F, Miao G, **Simuni T**; Parkinson's Foundation Quality Improvement Initiative Investigators. Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson's Disease by Expert Care Centers from 2010 to 2017: The Parkinson's Foundation Quality Improvement Initiative. *Mov Disord Clin Pract*. 2019 Oct 8;6(8):687-692. doi: 10.1002/mdc3.12837. eCollection 2019 Nov. PMID: 31745479
105. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, **Simuni T**, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. *Genet Med*. 2020 Feb;22(2):448. doi: 10.1038/s41436-019-0709-5. PMID: 31772350
106. Sokol LL, Young MJ, Papanian J, Kluger BM, Lum HD, Besbris J, Kramer NM, Lang AE, Espay AJ, Dubaz OM, Miyasaki JM, Matlock DD, **Simuni T**, Cerf M. Advance care planning in Parkinson's disease: ethical challenges and future directions. *NPJ Parkinsons Dis*. 2019 Nov 22;5:24. doi: 10.1038/s41531-019-0098-0. eCollection 2019. PMID: 31799376 Review.
107. Prakash N, McFarthing K, **Simuni T**. Clinical Trial Highlights - Infusion Therapies. *J Parkinsons Dis*. 2020;10(1):5-17. doi: 10.3233/JPD-199005. PMID: 31903996
108. **Simuni T**, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kiebertz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. *Mov Disord*. 2020 May;35(5):833-844. doi: 10.1002/mds.27989. Epub 2020 Feb 19. PMID: 32073681
109. Badawy R, Hameed F, Bataille L, Little MA, Claes K, Saria S, Cedarbaum JM, Stephenson D, Neville J, Maetzler W, Espay AJ, Bloem BR, **Simuni T**, Karlin DR. Metadata Concepts for Advancing the Use of Digital

- Health Technologies in Clinical Research. *Digit Biomark*. 2019 Oct 7;3(3):116-132. doi: 10.1159/000502951. eCollection 2019 Sep-Dec. PMID: 32175520
110. Cudkowicz M, Chase MK, Coffey CS, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner JM, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA; NeuroNEXT Clinical Study Sites; Shinnar S, Patch D, Darras BT, Ellis A, Packer RJ, Marder KS, Chiriboga CA, Henchcliffe C, Moran JA. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. *JAMA Neurol*. 2020 Jun 1;77(6):755-763. doi: 10.1001/jamaneurol.2020.0367. PMID: 32202612
 111. Parkinson Study Group STEADY-PD III Investigators. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. *Ann Intern Med*. 2020 May 5;172(9):591-598. doi: 10.7326/M19-2534. Epub 2020 Mar 31. PMID: 32227247 Clinical Trial.
 112. McFarthing K, Larson D, **Simuni T**. Clinical Trial Highlights - GLP-1 agonists. *J Parkinsons Dis*. 2020;10(2):355-368. doi: 10.3233/JPD-200002. PMID: 32250322 No abstract available.
 113. Archer DB, Bricker JT, Chu WT, Burciu RG, Mccracken JL, Lai S, Coombes SA, Fang R, Barmpoutis A, Corcos DM, Kurani AS, Mitchell T, Black ML, Herschel E, **Simuni T**, Parrish TB, Comella C, Xie T, Seppi K, Bohnen NI, Müller MLTM, Albin RL, Krismer F, Du G, Lewis MM, Huang X, Li H, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE. Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. *Lancet Digit Health*. 2019 Sep;1(5):e222-e231. doi: 10.1016/s2589-7500(19)30105-0. Epub 2019 Aug 27. PMID: 32259098
 114. Weintraub D, Caspell-Garcia C, **Simuni T**, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M; Parkinson's Progression Markers Initiative. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. *Ann Clin Transl Neurol*. 2020 Apr;7(4):449-461. doi: 10.1002/acn3.51022. Epub 2020 Apr 13. PMID: 32285645
 115. Shawen N, O'Brien MK, Venkatesan S, Lonini L, **Simuni T**, Hamilton JL, Ghaffari R, Rogers JA, Jayaraman A. Role of data measurement characteristics in the accurate detection of Parkinson's disease symptoms using wearable sensors. *J Neuroeng Rehabil*. 2020 Apr 20;17(1):52. doi: 10.1186/s12984-020-00684-4. PMID: 32312287
 116. Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, **Simuni T**, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek K, Trojanowski JQ, Shaw LM; Parkinson's Progression Marker Initiative. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. *Ann Neurol*. 2020 Sep;88(3):574-587. doi: 10.1002/ana.25811. Epub 2020 Jul 2. PMID: 32542885
 117. Prakash N, **Simuni T**. Infusion Therapies for Parkinson's Disease. *Curr Neurol Neurosci Rep*. 2020 Aug 1;20(9):44. doi: 10.1007/s11910-020-01062-2. PMID: 32740768 Review.
 118. Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, **Simuni T**, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. *Mov Disord*. 2020 Nov;35(11):1999-2008. doi: 10.1002/mds.28206. Epub 2020 Aug 15. PMID: 32798333
 119. Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, **Simuni T**, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson's Progression Markers Initiative. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. *Ann Clin Transl Neurol*. 2020 Oct;7(10):1816-1830. doi: 10.1002/acn3.51164. Epub 2020 Sep 5. PMID: 32888397

120. Tarolli CG, Andrzejewski K, Zimmerman GA, Bull M, Goldenthal S, Auinger P, O'Brien M, Dorsey ER, Biglan K, **Simuni T**. Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease. *J Parkinsons Dis*. 2020;10(4):1779-1786. doi: 10.3233/JPD-202163. PMID: 32894251
121. Mills KA, Schneider RB, Saint-Hilaire M, Ross GW, Hauser RA, Lang AE, Halverson MJ, Oakes D, Eberly S, Litvan I, Blindauer K, Aquino C, **Simuni T**, Marras C. Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. *Parkinsonism Relat Disord*. 2020 Nov;80:127-132. doi: 10.1016/j.parkreldis.2020.09.028. Epub 2020 Sep 20. PMID: 32987359
122. Prakash N, McFarthing K, **Simuni T**. Clinical Trial Highlights - Parkinson's Disease Cognition. *J Parkinsons Dis*. 2021;11(1):9-30. doi: 10.3233/JPD-209006. PMID: 33044194
123. **Simuni T**, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G; Parkinson Study Group NILO-PD Investigators and Collaborators. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol*. 2021 Mar 1;78(3):312-320. doi: 10.1001/jamaneurol.2020.4725. PMID: 33315105
124. Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogg B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kiebertz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, **Simuni T**, Iranzo A. Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. *Ann Clin Transl Neurol*. 2021 Jan;8(1):201-212. doi: 10.1002/acn3.51269. Epub 2020 Dec 15. PMID: 33321002
125. Roberts AC, Rafferty MR, Wu SS, Miao G, Cubillos F, **Simuni T**; Parkinson's Foundation Quality Improvement Initiative Investigators Steering Committee Members; PF QII Principal Investigators. Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. *Parkinsonism Relat Disord*. 2021 Feb;83:115-122. doi: 10.1016/j.parkreldis.2020.11.024. Epub 2020 Dec 4. PMID: 33339716
126. Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio A, Beck JC, Biglan K, Espay AJ, Tanner C, Oakes D, Shoulson I, Novak D, Kayson E, Ray Dorsey E, Mangravite L, Schwarzschild MA, **Simuni T**; Parkinson Study Group AT-HOME PD Investigators. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). *Ann Clin Transl Neurol*. 2021 Feb;8(2):308-320. doi: 10.1002/acn3.51236. Epub 2020 Dec 22. PMID: 33350601
127. Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain L, Bhatnagar R, Bloem BR, Boroojerdi B, Burton J, Cedarbaum JM, Cosman J, Dexter DT, Dockendorf M, Dorsey ER, Dowling AV, Evers LJW, Fisher K, Frasier M, Garcia-Gancedo L, Goldsack JC, Hill D, Hitchcock J, Hu MT, Lawton MP, Lee SJ, Lindemann M, Marek K, Mehrotra N, Meinders MJ, Minchik M, Oliva L, Romero K, Roussos G, Rubens R, Sadar S, Scheeren J, Sengoku E, **Simuni T**, Stebbins G, Taylor KI, Yang B, Zach N. Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. *Digit Biomark*. 2020 Nov 26;4(Suppl 1):28-49. doi: 10.1159/000512500. eCollection 2020 Winter. PMID: 33442579
128. Venuto CS, Yang L, Javidnia M, Oakes D, James Surmeier D, **Simuni T**. Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease. *Ann Clin Transl Neurol*. 2021 Mar;8(3):603-612. doi: 10.1002/acn3.51300. Epub 2021 Jan 18. PMID: 33460320
129. Larson DN, Schneider RB, **Simuni T**. A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson's Disease. *J Parkinsons Dis*. 2021;11(s1):S27-S34. doi: 10.3233/JPD-202381. PMID: 33492246
130. Khan U, Stoff L, Yahuaca JD, Bhagavat B, Toledo S, Goldman JG, **Simuni T**, Rafferty M. Evaluation of an Interdisciplinary Screening Program for People With Parkinson Disease and Movement Disorders. *Arch*

Rehabil Res Clin Transl. 2020 Jun 22;2(3):100067. doi: 10.1016/j.arret.2020.100067. eCollection 2020 Sep. PMID: 33543093

131. Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodríguez-Violante M, **Simuni T**, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C. Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. *J Parkinsons Dis.* 2021;11(2):395-404. doi: 10.3233/JPD-202472. PMID: 33682731
132. Prakash N, McFarthing K, **Simuni T**. Clinical Trial Highlights - Kinase Inhibitors. *J Parkinsons Dis.* 2021;11(2):377-390. doi: 10.3233/JPD-219003. PMID: 33749620
133. McFarthing K, Prakash N, **Simuni T**. Phase 3 in Focus - Amprelosetine, Theravance Biopharma. *J Parkinsons Dis.* 2021;11(2):391-393. doi: 10.3233/JPD-219004. PMID: 33749621
134. Kremer T, Taylor KI, Siebourg-Polster J, Gerken T, Staempfli A, Czech C, Dukart J, Galasko D, Foroud T, Chahine LM, Coffey CS, **Simuni T**, Weintraub D, Seibyl J, Poston KL, Toga AW, Tanner CM, Marek K, Hutten SJ, Dziadek S, Trenkwalder C, Pagano G, Mollenhauer B. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. *Mov Disord.* 2021 Aug;36(8):1972-1978. doi: 10.1002/mds.28608. Epub 2021 May 4. PMID: 33942926
135. Cook L, Schulze J, Kopil C, Hastings T, Naito A, Wojcieszek J, Payne K, Alcalay RN, Klein C, Saunders-Pullman R, **Simuni T**, Foroud T. Genetic Testing for Parkinson Disease: Are We Ready? *Neurol Clin Pract.* 2021 Feb;11(1):69-77. doi: 10.1212/CPJ.0000000000000831. PMID: 33968475
136. Marras C, Mills KA, Eberly S, Oakes D, Chou KL, Halverson M, Parashos SA, Tarolli CG, Lai JS, Nowinsky CJ, Suchowersky O, Farbman ES, Shulman LM, **Simuni T**. Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease. *Mov Disord.* 2021 Aug;36(8):1979-1983. doi: 10.1002/mds.28641. Epub 2021 May 13. PMID: 33983638
137. Vijjaratnam N, **Simuni T**, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. *Lancet Neurol.* 2021 Jul;20(7):559-572. doi: 10.1016/S1474-4422(21)00061-2. PMID: 34146514 Review.
138. Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, **Simuni T**, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs Orenbach S, Rosenfeld O, Sasson N, Yardeni T, Espay AJ; BeyoND study group. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. *Mov Disord.* 2021 Nov;36(11):2687-2692. doi: 10.1002/mds.28758. Epub 2021 Sep 8. PMID: 34496081
139. Parkinson Study Group SURE-PD3 Investigators; Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, **Simuni T**, Pothier L, Waikar SS, Lang A, Mestre T. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. *JAMA.* 2021 Sep 14;326(10):926-939. doi: 10.1001/jama.2021.10207. PMID: 34519802
140. Manes JL, Herschel E, Aveni K, Tjaden K, Parrish T, **Simuni T**, Corcos DM, Roberts AC. The effects of a simulated fMRI environment on voice intensity in individuals with Parkinson's disease hypophonia and older healthy adults. *J Commun Disord.* 2021 Nov-Dec;94:106149. doi: 10.1016/j.jcomdis.2021.106149. Epub 2021 Aug 31. PMID: 34543846
141. Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, Schwarzschild MA, Sieber BA, **Simuni T**, Surmeier DJ, Tamiz A, Werner MH, Wright CB, Wyse R. Seeking progress in disease

- modification in Parkinson disease. *Parkinsonism Relat Disord*. 2021 Sep;90:134-141. doi: 10.1016/j.parkreldis.2021.09.006. Epub 2021 Sep 10. PMID: 34561166 Review.
142. Luo S, Zou H, Goetz CG, Choi D, Oakes D, **Simuni T**, Stebbins GT. Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models. *Mov Disord Clin Pract*. 2021 Aug 3;8(7):1083-1091. doi: 10.1002/mdc3.13311. eCollection 2021 Oct. PMID: 34631944
143. Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, **Simuni T**, Marek K, Koller M, Seigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. *Front Neurol*. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. PMID: 34659081
144. Larson D, **Simuni T**. New dopaminergic therapies for PD motor complications. *Neuropharmacology*. 2022 Feb 15;204:108869. doi: 10.1016/j.neuropharm.2021.108869. Epub 2021 Nov 3. PMID: 34742740 Review.
145. Surmeier DJ, Nguyen JT, Lancki N, Venuto CS, Oakes D, **Simuni T**, Wyse RK. Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease. *Mov Disord*. 2022 Feb;37(2):334-342. doi: 10.1002/mds.28850. Epub 2021 Nov 12. PMID: 34766657
- 2022**
146. Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillie S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, **Simuni T**, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. *J Parkinsons Dis*. 2022;12(2):557-570. doi: 10.3233/JPD-212714. PMID: 34897099
147. **Simuni T**, Okun MS. Adjunctive Therapies in Parkinson Disease-Have We Made Meaningful Progress? *JAMA Neurol*. 2022 Feb 1;79(2):119-120. doi: 10.1001/jamaneurol.2021.4140. PMID: 34962569 No abstract available.
148. Tosin MHS, **Simuni T**, Stebbins GT, Cedarbaum JM. Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson's Disease? *J Parkinsons Dis*. 2022;12(4):1345-1351. doi: 10.3233/JPD-223170. PMID: 35466955
149. Mitchell T, Wilkes BJ, Archer DB, Chu WT, Coombes SA, Lai S, McFarland NR, Okun MS, Black ML, Herschel E, **Simuni T**, Comella C, Afshari M, Xie T, Li H, Parrish TB, Kurani AS, Corcos DM, Vaillancourt DE. Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Neuroimage Clin*. 2022;34:103022. doi: 10.1016/j.nicl.2022.103022. Epub 2022 Apr 26. PMID: 35489192
150. Luo S, Zou H, Stebbins GT, Schwarzschild MA, Macklin EA, Chan J, Oakes D, **Simuni T**, Goetz CG; Parkinson Study Group SURE-PD3 Investigators. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. *Mov Disord*. 2022 Sep;37(9):1904-1914. doi: 10.1002/mds.29154. Epub 2022 Jul 16. PMID: 35841312
151. Zou H, Aggarwal V, Stebbins GT, Müller MLTM, Cedarbaum JM, Pedata A, Stephenson D, **Simuni T**, Luo S. Application of longitudinal item response theory models to modeling Parkinson's disease progression. *CPT Pharmacometrics Syst Pharmacol*. 2022 Oct;11(10):1382-1392. doi: 10.1002/psp4.12853. Epub 2022 Aug 9. PMID: 35895005
152. Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, **Simuni T**, Dam T; SPARK

- Investigators. Trial of Cinpanemab in Early Parkinson's Disease. *N Engl J Med*. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395. PMID: 35921450
153. Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, **Simuni T**, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Trial of Prasinezumab in Early-Stage Parkinson's Disease. *N Engl J Med*. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. PMID: 35921451
154. Berg D, Crotty GF, Keavney JL, Schwarzschild MA, **Simuni T**, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. *Neurology*. 2022 Aug 16;99(7 Suppl 1):76-83. doi: 10.1212/WNL.0000000000200793. PMID: 35970586
155. Hopfner F, Tietz AK, Ruf VC, Ross OA, Koga S, Dickson D, Aguzzi A, Attems J, Beach T, Beller A, Cheshire WP, van Deerlin V, Desplats P, Deuschl G, Duyckaerts C, Ellinghaus D, Evsyukov V, Flanagan ME, Franke A, Frosch MP, Gearing M, Gelpi E, van Gerpen JA, Ghetti B, Glass JD, Grinberg LT, Halliday G, Helbig I, Höllerhage M, Huitinga I, Irwin DJ, Keene DC, Kovacs GG, Lee EB, Levin J, Martí MJ, Mackenzie I, McKeith I, Mclean C, Mollenhauer B, Neumann M, Newell KL, Pantelyat A, Pendziwiat M, Peters A, Molina Porcel L, Rabano A, Matěj R, Rajput A, Rajput A, Reimann R, Scott WK, Seeley W, Selvackadunco S, **Simuni T**, Stadelmann C, Svenningsson P, Thomas A, Trenkwalder C, Troakes C, Trojanowski JQ, Uitti RJ, White CL, Wszolek ZK, Xie T, Ximelis T, Yebenes J; Alzheimer's Disease Genetics Consortium; Müller U, Schellenberg GD, Herms J, Kuhlenbäumer G, Höglinger G. Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy. *Mov Disord*. 2022 Oct;37(10):2110-2121. doi: 10.1002/mds.29164. Epub 2022 Aug 23. PMID: 35997131
156. Atri R, Urban K, Marebwa B, **Simuni T**, Tanner C, Siderowf A, Frasier M, Haas M, Lancashire L. Deep Learning for Daily Monitoring of Parkinson's Disease Outside the Clinic Using Wearable Sensors. *Sensors (Basel)*. 2022 Sep 9;22(18):6831. doi: 10.3390/s22186831. PMID: 36146181
157. Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, **Simuni T**, Marek K, Naito A, Lungu C, Corcos DM; SPARX3-PSG Investigators. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. *Trials*. 2022 Oct 6;23(1):855. doi: 10.1186/s13063-022-06703-0. PMID: 36203214
158. **Simuni T**, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson's Progression Marker Initiative Authors. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort. *NPJ Parkinsons Dis*. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. PMID: 36273008
159. Keller Sarmiento IJ, Afshari M, Kinsley L, Silani V, Akhtar RS, **Simuni T**, Lubbe SJ, Krainc D, Mencacci NE. Novel bi-allelic FBXO7 variants in a family with early-onset typical Parkinson's disease. *Parkinsonism Relat Disord*. 2022 Nov;104:88-90. doi: 10.1016/j.parkreldis.2022.10.014. Epub 2022 Oct 13. PMID: 36274328
160. Galasko D, **Simuni T**. Lack of Benefit of Iron Chelation in Early Parkinson's Disease. *N Engl J Med*. 2022 Dec 1;387(22):2087-2088. doi: 10.1056/NEJMe2213120. PMID: 36449427

161. Chahine LM, **Simuni T**. Role of novel endpoints and evaluations of response in Parkinson disease. *Handb Clin Neurol*. 2023;193:325-345. doi: 10.1016/B978-0-323-85555-6.00010-2. PMID: 36803820
162. **Simuni T**, Merchant K. A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease. *Parkinsonism Relat Disord*. 2023 Feb 16;105325. doi: 10.1016/j.parkreldis.2023.105325. PMID: 36809869
163. Merchant KM, **Simuni T**, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, Sherer T, Mollenhauer B, Siderowf A, Tanner C, Marek K; the Parkinson's Progression Markers Initiative. LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. *NPJ Parkinsons Dis*. 2023 Feb 28;9(1):30. doi: 10.1038/s41531-023-00468-2.PMID: 36854767
164. Di Luca DG, Macklin EA, Hodgeman K, Lopez G, Pothier L, Callahan KF, Lowell J, Chan J, Videnovic A, Lungu C, Lang AE, Litvan I, Schwarzschild MA, **Simuni T**. Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials. *Neurol Clin Pract*. 2023 Feb;13(1):e200113. doi: 10.1212/CPJ.0000000000200113. Epub 2023 Jan 18.PMID: 36865634
165. Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, **Simuni T**. Proposal for a Biologic Staging System of Parkinson's Disease. *J Parkinsons Dis*. 2023 Apr 10. doi: 10.3233/JPD-225111. PMID: 37066922
166. Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, **Simuni T**, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α -synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6.PMID: 37059509
167. Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kieburz K, Marek K, Merchant K, Mollenhauer B, Poston KL, **Simuni T**, Siderowf A, Singleton A, Seibyl J, Tanner CM; Parkinson's Progression Markers Initiative. Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study. *Mov Disord Clin Pract*. 2023 Apr 25;10(6):943-955. doi: 10.1002/mdc3.13751. 2023 Jun. PMID: 37332638
168. Saunders-Pullman R, Raymond D, Ortega RA, Shalash A, Gatto E, Salari M, Markgraf M, Alcalay RN, Mascalzoni D, Mencacci NE, Bonifati V, Merello M, Chung SJ, Novakovic I, Bardien S, Pal G, Hall A, Hattori N, Lynch T, Thaler A, Sue CM, Foroud T, Verbrugge J, Schulze J, Cook L, Marder K, Suchowersky O, Klein C, **Simuni T**. International Genetic Testing and Counseling Practices for Parkinson's Disease. *Mov Disord*. 2023 Aug;38(8):1527-1535. doi: 10.1002/mds.29442. Epub 2023 Jun 13. PMID: 37310233
169. Pal G, Cook L, Schulze J, Verbrugge J, Alcalay RN, Merello M, Sue CM, Bardien S, Bonifati V, Chung SJ, Foroud T, Gatto E, Hall A, Hattori N, Lynch T, Marder K, Mascalzoni D, Novaković I, Thaler A, Raymond D, Salari M, Shalash A, Suchowersky O, Mencacci NE, **Simuni T**, Saunders-Pullman R, Klein C. Genetic Testing in Parkinson's Disease. *Mov Disord*. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27. PMID: 37365908
170. Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, Höglinger GU, Marek K, Pacchetti C, Schapira AHV, Scherzer CR, **Simuni T**, Minini P, Sardi SP, Peterschmitt MJ. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2023 Aug;22(8):661-671. doi: 10.1016/S1474-4422(23)00205-3. PMID: 37479372
171. Qi R, Sammler E, Gonzalez-Hunt CP, Barraza I, Pena N, Rouanet JP, Naaldijk Y, Goodson S, Fuzzati M, Blandini F, Erickson KI, Weinstein AM, Lutz MW, Kwok JB, Halliday GM, Dzamko N, Padmanabhan S, Alcalay RN, Waters C, Hogarth P, **Simuni T**, Smith D, Marras C, Tonelli F, Alessi DR, West AB, Shiva S, Hilfiker S, Sanders LH. A blood-based marker of mitochondrial DNA damage in Parkinson's disease. *Sci Transl Med*. 2023 Aug 30;15(711):eabo1557. doi: 10.1126/scitranslmed.abo1557. Epub 2023 Aug 30. PMID: 37647388
172. Jackson H, Anzures-Cabrera J, **Simuni T**, Postuma RB, Marek K, Pagano G. Identifying prodromal symptoms at high specificity for Parkinson's disease. *Front Aging Neurosci*. 2023 Sep 22;15:1232387. doi: 10.3389/fnagi.2023.1232387. eCollection 2023. PMID: 37810617

173. Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Beck JC, Naito A, Hall A, Chan AK, Casaceli CJ, Marder K, Nance M, Schwarzschild MA, **Simuni T**, Wills AM, Alcalay RN; Parkinson's Foundation and Parkinson's Study Group (PSG). Providing genetic testing and genetic counseling for Parkinson's disease to the community. *Genet Med*. 2023 Oct;25(10):100907. doi: 10.1016/j.gim.2023.100907. Epub 2023 Jun 8. PMID: 37302021
174. Brumm MC, Siderowf A, **Simuni T**, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kiebertz K, Marek K, Coffey CS; Parkinson's Progression Markers Initiative. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis*. 2023;13(6):899-916. doi: 10.3233/JPD-223433. PMID: 37458046
175. Mirelman A, Rochester L, **Simuni T**, Hausdoff JM. Digital mobility measures to predict Parkinson's disease. *Lancet Neurol*. 2023 Dec;22(12):1098-1100. doi: 10.1016/S1474-4422(23)00376-9. Epub 2023 Oct 18. PMID: 37865117
176. Marras C, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, Van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Mollenhauer B, Postuma RB, Rodríguez-Violante M, **Simuni T**, Weintraub D, Lawton M, Mestre TA. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach. *Mov Disord*. 2024 Jan 20. doi: 10.1002/mds.29708. Online ahead of print. PMID: 38243775
177. **Simuni T**, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kiebertz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. A biological definition of neuronal α -synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. PMID: 38267190
178. Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, **Simuni T**, Foroud TM, Toga AW, Tanner CM, Kiebertz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM; Parkinson's Progression Markers Initiative. Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. *Neurology*. 2024 Feb;102(4):e208033. doi: 10.1212/WNL.0000000000208033. Epub 2024 Feb 2. PMID: 38306599

Publications as part of the participation in multicenter studies:

1. Parkinson Study Group Investigators (**Simuni**). Mixed lineage kinase inhibitor **CEP-1347** fails to delay disability in early Parkinson disease. 2007; *Neurology* **69**(15): 1480-90.
2. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group **PRECEPT** Investigators (**Simuni**), Hyson C, Gorbald E, Rudolph A, Kiebertz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. *Arch Neurol*. 2008 Jun;65(6):716-23. PMID: 18413464.
3. Shifitto, Friedman, Oakes, Shulman, Fahn. Parkinson Study Group ELLDOPA Investigators (**Simuni**). Fatigue in levodopa-naive subjects with Parkinson disease. *Neurology* 2008 Aug 12; 71: 481-5. PMID: 18695158.
4. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM; **Istradefylline 6002-US-013 Study Group (Simuni)**. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. *Mov Disord*. 2008 Nov 15;23(15):2177-85. PMID: 18831530.
5. Pankratz N, Marder KS, Halter C, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study Group-**PROGENI** Investigators (**Simuni**). Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord*. 2008. Nov 15;23(15):2216-23. PMID: 18785635.
6. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, PSG **PROGENI** and GenePD Investigators (**Simuni**), Coordinators and Molecular Genetic Laboratories. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. *Hum Genet*. 2009 Jan;124(6):593-605. PMID: 18985386.
7. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T; Parkinson Study Group-**PROGENI** Investigators (**Simuni**). Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. *Neurology* 2009. Jan 27;72(4):310-6. PMID:

18987351.

8. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T; Parkinson Study Group **PROGENI** Investigators (**Simuni**). Variation in GIGYF2 is not associated with Parkinson's disease. *Neurology*. 2009 Jun 2;72(22):1886-92. PMID: 19279319.
9. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Roroud T, Nichols WC; Parkinson Study Group **PROGENI** Investigators (**Simuni**). Parkinson dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. *Neurology*. 2009 Jul 28;73(4):279-86. PMID: 19636047.
10. Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Roroud T; **PROGENI** Investigators (**Simuni**), Coordinators and Molecular Genetic Laboratories; GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for onset age in Parkinson's disease. *BMC Med Genet*. 2009 Sep 22;10:98. PMID: 19772629.
11. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; **ADAGIO** Study Investigators (**Simuni**). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. *N Engl J Med*. 2009 Sep 24;361(13):1268-78. PMID: 19776408.
12. Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group **LABS-PD** Investigators (**Simuni**). A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. *Mov Disord*. 2009 Oct 30;24(14):2081-90. PMID: 19691116.
13. Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group **DATATOP** and **PRECEPT** Investigators (**Simuni**). A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. *Mov Disord*. 2009 Dec 15;24(16):2370-8. PMID: 19908310.
14. Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM; **Istradefylline 6002-US-007 Study Group (Simuni)**. A long term study of istradefylline in subjects with fluctuating Parkinson's disease. *Parkinsonism Relat Disord*. 2010 Jul; 16(6):423-6. PMID: 20338800.
15. Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Roroud T; Parkinson Study Group **PROGENI** Investigators (**Simuni**). Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. *BMC Med Genet*. 2010 Apr 1;11:53. PMID: 20356410.
16. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; **Sentinel Investigators (Simuni)**. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci*. 2010 May 15;292(1-2):28-35. PMID: 20236661.
17. Shwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG **PRECEPT** Investigators (**Simuni**), Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Lang A, Fahn S, Gauger L, Goetz C. Cancer incidence in a trial of an antipoptotic agent for Parkinson's disease. *Mov Disord*. 2010 Dec 15, 25(12):1801-8. PMID: 20669311.
18. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group **DATATOP** and **PRECEPT** investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. *Mov Disord*. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1. PMID: 21287602
19. Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-**PROGENI** and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. *PLoS One*. 2011;6(8):e20988. Epub 2011 Aug 2. PMID: 21829596
20. Lew MF, Somogyi M, McCague K, Welsh M; Lce QoL Study Group. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. *Int J Neurosci*. 2011 Nov;121(11):605-13. Epub 2011 Aug 16. PMID: 21843110
21. Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K; **PARS** Investigators. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. *Mov Disord*. 2012

- Mar;27(3):406-12. doi: 10.1002/mds.24892. PMID: 22237833.
22. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Iverson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Ann Neurol*. 2012 Mar;71(3):370-84. PMID: 22451204.
 23. Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, Bethoux F, Heinemann A, Rubin S, Cavazos JE, Reder AT, Sufit R, **Simuni T**, Holmes GL, Siderowf A, Wojna V, Bode R, McKinney N, Podrabsky T, Wortman K, Choi S, Gershon R, Rothrock N, Moy C. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. *Neurology*. 2012 Jun 5;78(23):1860-7. PMID: 22573626
 24. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. *Mov Disord*. 2012 Oct;27(12):1513-21. PMID: 23079770.

Selected Editorials, Reviews, Chapters, Books:

1. **Simuni T**, Stern MB. Does levodopa accelerate Parkinson's disease? *Drugs Aging*. 1999 Jun;14(6):399-408. Review. PMID: 10408739
2. **Simuni T**, Hurtig H: Parkinson's Disease: The Clinical Picture. Chapter 10. In: *Neurodegenerative Dementias*. Ed. J. Trojanowski, C. Clark. McGraw Hill Companies. 2000.
3. **Simuni T**, Hurtig H. Levodopa: 30 years of progress. In: *Parkinson's Disease in the New Millennium*. Ed. S. Factor. 2001
4. **Simuni T**. Tremor. In: *Clinical Neurology of the older adult*. Eds: Sirven J, Malamut B., Lippincott, Williams and Wilkins, 2001.
5. Colcher A, **Simuni T**. Other Parkinson syndromes. *Neurol Clin*. 2001 Aug;19(3):629-49, vii. Review. PMID: 11532647.
6. **Simuni T**, Martinez K, Rogers M. Physical and Occupational therapy in Parkinson's disease. In: *Therapy of Parkinson's disease*. Eds: Pahwa , Lyons K, Koller W. Marcel Dekker, 2004.
7. Fernandez HH and **Simuni T**. Chapter IIA: Anxiety in Parkinson's Disease. In: Pfeiffer RF, Bodis-Wollner I, eds. *Parkinson's Disease and Nonmotor Dysfunction*. The Humana Press, Inc. Totowa, NJ. 2005
8. **Simuni T**. Physical and occupational therapy in essential tremor. Chapter. *Essential tremor and other Tremor disorders*. Eds: Pahwa, Lyons. Marcell Decker, 2005
9. **Simuni T**. Chemodenervation: Botulinum toxin. Chapter 9. In: Baltuch G, Stern MB, eds. *Surgical management of movement disorders*. Marcel Decker 2006
10. **Simuni T**, Hurtig H.: Parkinson's Disease: The Clinical Picture. Chapter 10. In: *Neurodegenerative Dementias*. Ed. J. Trojanowski, C. Clark. McGraw Hill Companies. 2006, 2nd edition.
11. **Simuni T**. Tremor. In: *Clinical Neurology of the older adult*. Eds: Sirven J, Malamut B., Lippincott, Williams and Wilkins, 2007
12. **Simuni T**, Weaver F. Subthalamic nucleus deep brain stimulation for Parkinson's disease. Motor outcomes. In: *Deep brain stimulation for Parkinson's disease*. Eds: Baltuch G, Stern MB.
13. **Simuni T**, Pahwa R. Co-Editors. *Management of Parkinson's disease*. Monograph. Oxford University Press. 2009.
14. **Simuni T**. Fernandez HH .Chapter IIA: Anxiety in Parkinson's Disease. In: Pfeiffer RF, Bodis-Wollner I, eds. *Parkinson's Disease and Nonmotor Dysfunction*. The Humana Press, Inc. Totowa , NJ. 2010 second edition.
15. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). *Prog Neurobiol*. 2011 Dec;95(4):629-35. Review. PMID: 21930184.
16. Yasaman Kianirad, **Tanya Simuni**. Pimavanserin, new medication for treating hallucination and psychosis experienced in Parkinson's patients: clinical review.

Selected Online Publications (peer reviewed):

1. **Simuni T**. Neuroprotective studies in Parkinson's disease. MEDScape CME online publication. 2009

2. **Simuni T.** Non motor manifestations of Parkinson's disease. MEDScape CME on line publication. 2010
3. **Simuni T.** Early Interventions in Parkinson's disease. MEDScape CME online publication. 2010
4. Surmeier DJ, **Simuni T.** Neuroprotection in Parkinson's disease. Frontiers. Online publication. 2010
5. **Simuni T,** Spies W. DAT imaging studies in Parkinson's disease. MEDScape CME online publication. 2013
6. Oustwani CS, Korutz AW, Lester MS, Kianirad Y, **Simuni T,** Hijaz TA. Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes? Clin Imaging. 2017 Jul - Aug;44:66-69. PMID: 28460362
7. Biglan K, **Simuni T.** Movement Disorders Focus: Harnessing Existing Drugs to Slow Progression of Parkinson's Disease: The STEADY-PDIII Trial of Isradipine. *Practical Neurology* online publication. June 2015
8. Kianirad Y, **Simuni T.** Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Expert Rev Clin Pharmacol. 2017 Aug 18. 28817967.

Selected Posters and Abstracts (last 5 years)

1. **T. Simuni,** B. Fiske, K. Merchant, C. Coffey S, H. Matthews, R. Wyse K, P. Brundin, D. Simon K-, M. Schwarzschild, D. Weiner, J. Adams, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff. A phase 2A Study of Nilotinib in patients with advanced and early Parkinson's Disease: Study Design (NILO). Lisbon, Portugal. March 27, 2019
2. **T Simuni,** Fiske B, Merchant K, Coffey C, Matthews H, Wyse R, Brundin P, Simon DK, Schwarzschild MA, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, Rafaloff G. A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's disease. Study design. PD Therapeutics Conference (MJFF). New York City. October 25, 2019
3. **T Simuni,** Marek K, Siderowf A, Lafontant DE, Caspell-Garcia C, Coffey C, Mollenhauer B, Tanner C, Kieburz K, Chahine L, Seibyl J. Longitudinal Characterization of the Clinical and DAT Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort. American Academy of Neurology Annual Meeting. Philadelphia. May 5, 2019
4. **T Simuni,** Fischer T, Gasser T, Isaacson S, Kulisevsky J, Mir P, Wills AM, Correia Guedes L, Svenningsson P, Waters C, Ji A, Li J, Minini P, Nembo B, Sardi SP, Saubadu S, Sharma J, Peterschmitt MJ. Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson's disease patients with a GBA mutation. American Academy of Neurology Annual Meeting. Philadelphia. May 5, 2019
5. **T Simuni,** Shawen N, Knott J, Lee J, Daeschler D, Jayaraman A. Automatic Scoring of Parkinson's Disease Motor Symptoms Using a Smartwatch. American Academy of Neurology Annual Meeting. Philadelphia. May 6, 2019
6. **T Simuni,** Schneider R, Anthwal S, Kayson E, Omberg L, Tarolli C, Macklin E, Bataille L, Dorsey ER, Mangravite L, Schwarzschild M. Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson's Disease Trials (AT-HOME PD): Initiation of a Long-Term Observational Study. American Academy of Neurology Annual Meeting. Philadelphia. May 6, 2019
7. **T Simuni,** Fiske B, Merchant K, Coffey C, Matthews H, Wyse K, Brundin P, Simon D, Schwarzschild M, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, Rafaloff G. NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update. American Academy of Neurology Annual Meeting. Philadelphia. May 7, 2019
8. **T Simuni,** Larson D, Yu M, Margolius A, Gao H, Rafferty M, Roberts A, Wu S. Intensity-based exercise groupings in Parkinson's Disease: Analysis from the Parkinson's Foundation Quality Improvement Initiative (PF-QII). American Academy of Neurology Annual Meeting. Philadelphia. May 7, 2019
9. **T Simuni,** Siderowf A, Uribe L, Caspell-Garcia C, Coffey C, Foroud T, Mollenhauer B, Tanner C, Kieburz K, Chahine L, Marek K. Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort. American Academy of Neurology Annual Meeting. Philadelphia. May 8, 2019
10. **T Simuni,** Dubaz O, Wu S, Miao G. Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson's Disease by Expert Care Centers From 2010 to 2017: The Parkinson's Foundation Quality Improvement Initiative (PF-QII). American Academy of Neurology Annual Meeting. Philadelphia. May 9, 2019

11. **T Simuni**, Yu M, Larson D, Roberts A, Sadural A, Fowler B, Gao H, Wu S, Rafferty M. Factors contributing to the sustainment of exercise in patients with Parkinson's Disease. The Parkinson's Foundation Quality Improvement Initiative (PF-QII) dataset. American Academy of Neurology Annual Meeting. Philadelphia. May 9, 2019
12. **T Simuni**, Holloway R, Oakes D., Hodgeman K., Greco B., Henderson S., Biglan K., Lowell J., Tarolli C., Lungus C. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Final study results. World Parkinson's Congress. Kyoto, Japan. June, 5, 2019.
13. **T Simuni**, Fiske B, Merchant K, Coffey C, Matthews H, Wyse K, Brundin P, Simon D, Schwarzschild M, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, Rafaloff G. NILO-PD: A Phase 2A Study of Nilotinib in Patients with Early Parkinson's Disease: Study Design and Status Update. International Congress of Parkinson's disease and Movement Disorders, Nice, France, September 23, 2019.
14. **T Simuni** , Holloway R. , Oakes D., Hodgeman K., Greco B., Henderson S., Biglan K., Lowell J., Tarolli C., Lungus C. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Final study results. International Congress of Parkinson's disease and Movement Disorders, Nice, France, September 23, 2019.
15. **T Simuni**, Siderowf A, Uribe L, Caspell-Garcia C, Coffey C, Foroud T, Mollenhauer B, Tanner C, Kiebertz K, Chahine L, Marek K. Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort. International Congress of Parkinson's disease and Movement Disorders, Nice, France, September 24, 2019.
16. **T Simuni**, Larson D, Yu M, Margolius A, Gao H, Rafferty M, Roberts A, Wu S. Intensity-based exercise groupings in Parkinson's Disease: Analysis from the Parkinson's Foundation Quality Improvement Initiative (PF-QII). International Congress of Parkinson's disease and Movement Disorders, Nice, France, September 25, 2019.
17. The Parkinson's Study Group, NILO-PD Investigators (**T Simuni**). NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease American Neurological Association Annual Meeting (ANA2019), St. Louis, Missouri, October 14, 2019
18. The Parkinson's Study Group, NILO-PD Investigators (**T Simuni**). NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease: Final Study Results, MDS-PAS Annual Meeting, February 2020
19. AAT-AD-PD 2020. NILO-PD PK & Dopamine Metabolites data 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders AD/PD 2020, Virtual Programming, April 2020
20. The Parkinson's Study Group, NILO-PD Investigators (**T Simuni**). "Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson's Disease". International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2020
21. PPMI Investigators (**T Simuni**). Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort. International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2020
22. The Parkinson's Study Group. NILO-PD PK & Dopamine Metabolites data. International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2020
23. T Simuni. Overview of clinical phenotypes of genetic PD common mutations. American Academy of Neurology Annual Meeting, Virtual Programming. October 2020
24. The Parkinson's Study Group, NILO-PD Investigators (**T Simuni**). NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease: Final Study Results, American Academy of Neurology Annual Meeting, Virtual Programming. October 2020
25. PPMI Investigators (**T Simuni**) "Defining LRRK2-PD subsets based on olfactory function in the PPMI". International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2021
26. PPMI Investigators (**T Simuni**) "Parkinson Progression Marker Initiative – New Science/New Cohorts". International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2021
27. T. Mestre, S. Eberly, C. Grimes, D. Oakes, **T. Simuni** "Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease". International Congress of Parkinson's disease and Movement Disorders, Virtual Programming. September 2021

28. T Simuni. Scientific Session: “Are we ready for PD prevention studies?” World Congress of Neurology (WCN 2021). October 2021
29. T Simuni. Scientific Session: “Near future treatment of Parkinson’s disease” World Congress of Neurology (WCN 2021). October 2021
30. The Parkinson’s Study Group. (**T Simuni**) GBA and LRRK2 targeting therapies: rationale and trial update. Virtual XXVI World Congress on Parkinson's Disease and Related Disorders (IAPRD), May 2022.
31. The Parkinson’s Study Group. (**T Simuni**) A 104-week delayed-start analysis of PASADENA Phase II study evaluating the safety and efficacy of prasinezumab in early-stage Parkinson's disease. 2022 Annual Parkinson’s Study Group Meeting. June 2022
32. Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort. International Congress of Parkinson’s disease and Movement Disorders, Madrid. September 2022
33. Bis(monoacylglycerol) phosphate levels are elevated at baseline in carriers of pathogenic variants in LRRK2 and GBA1 and do not predict progression of PD in PPMI cohorts. International Congress of Parkinson’s disease and Movement Disorders, Madrid. September 2022
34. Longitudinal Clinical And Biomarkers Characteristics Of Non-manifesting GBA1 N409S Carriers: The PPMI Cohort. AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. April 2023
35. Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design. International Congress of Parkinson’s disease and Movement Disorders, Copenhagen. August 2023.